

Aptima® Chlamydia trachomatis Assay

Instructions for Use
For *in vitro* diagnostic use
For U.S. Export only

General Information	2
Intended Use	2
Summary and Explanation of the Test	2
Principles of the Procedure	3
Summary of Safety and Performance	3
Warnings and Precautions	4
Reagent Storage and Handling Requirements	8
Specimen Collection and Storage	8
Panther System	11
Reagents and Materials Provided	11
Materials Required But Available Separately	12
Optional Materials	13
Panther System Test Procedure	13
Procedural Notes	16
Test Interpretation — QC/Patient Results	18
Limitations	21
Clinical Study Results	23
Expected Values	24
Prevalence	24
Positive and Negative Predictive Values for Hypothetical Prevalence Rates in North America	25
Aptima CT Assay on the DTS System RLU Distribution	26
DTS System Clinical Performance	28
Clinical Specimen Study — Endocervical Swab, Male Urethral Swab, Vaginal Swab, and Urine Specimens	28
DTS System Clinical Performance	28
RLU Distribution of Aptima Controls	38
Panther System Clinical Performance	40
Clinical Study	40
Performance Results	40
Chlamydia trachomatis Infected Status Tables	42
RLU Distribution of Aptima Chlamydia trachomatis Assay Controls	44
Reproducibility Study	45
Clinical Specimen Agreement	46
Analytical Performance	49
Spiked Clinical Panel Agreement Study	49
Analytical Sensitivity Study	49
Analytical Specificity	49
Analytical Specificity Equivalence Study	51
Interfering Substances	51
Interfering Substances Equivalence Study	51
Recovery	51
Precision/Reproducibility Study	51
Carryover Study	52
Specimen Stability Studies	52
Bibliography	54
Contact Information and Revision History	56

General Information

Intended Use

The Aptima® Chlamydia trachomatis Assay is a target amplification nucleic acid probe test that utilizes target capture and Transcription Mediated Amplification (TMA™) Technology for the *in vitro* qualitative detection of ribosomal RNA (rRNA) from *Chlamydia trachomatis* (CT) to aid in the diagnosis of chlamydial urogenital disease using the Panther® System. The assay may be used to test the following specimens from symptomatic and asymptomatic individuals: clinician-collected endocervical, vaginal and male urethral swab specimens; patient-collected vaginal¹ swab specimens; and female and male urine specimens. This assay is also intended for use with the testing of gynecological specimens, from both symptomatic and asymptomatic patients, collected in PreservCyt® Solution.

¹Patient-collected vaginal swab specimens are an option for screening women when a pelvic exam is not otherwise indicated.

Summary and Explanation of the Test

Chlamydia trachomatis infections are one of the most common sexually transmitted infections worldwide. In the United States alone, an estimated 1,579,885 (481.3 cases per 100,000 population) new cases of CT infections were reported to the Centers for Disease Control and Prevention (CDC) in 2020 (4).

Chlamydiae are nonmotile, gram-negative, obligate intracellular bacteria. The CT species is comprised of fifteen serovars (A, B, Ba, C, D, E, F, G, H, I, J, K, L1, L2 and L3) that can cause disease in humans (27). The serovars D through K are the major cause of genital chlamydial infections in men and women (19). *C. trachomatis* can cause nongonococcal urethritis, epididymitis, proctitis, cervicitis, acute salpingitis, and pelvic inflammatory disease (3, 11, 21, 22). *C. trachomatis* infections are often asymptomatic in both males and females. Children born to infected mothers are at significantly higher risk for inclusion conjunctivitis and chlamydial pneumonia (1, 8, 20).

Historically, several methods for CT detection have been utilized in the clinical laboratory, including cell culture, direct fluorescent antibody testing, enzyme immunoassay, and direct DNA probe assays. More recent methodologies for CT detection utilize nucleic acid amplification tests (NAATs). Cell culture was once considered to be the “gold standard” for detection of CT. Culture is quite specific, but publications have demonstrated that NAATs have a higher clinical sensitivity than culture (2, 7, 12, 23). Due to its lower clinical sensitivity and variable performance between laboratories, culture has been replaced in many laboratories by NAATs.

First generation NAATs for CT have technological issues that have limited their performance. These issues include cumbersome specimen processing and specimen inhibition that can yield false negative results (5, 10, 13, 18, 24, 25, 26). The Aptima Chlamydia trachomatis assay (Aptima CT assay) is a second generation NAAT that utilizes target capture, TMA, and Hybridization Protection Assay (HPA) technologies to streamline specimen processing, amplify target rRNA, and detect amplicon, respectively.

Studies comparing performance and specimen inhibition of various amplification systems have demonstrated the benefits of target capture, TMA, and HPA (6, 9).

Principles of the Procedure

Specimens are collected and transferred into their respective specimen transport tubes. The transport solution in these tubes releases the rRNA target and protects it from degradation during storage. When the Aptima CT assay is performed in the laboratory, the target rRNA molecule is isolated from the specimens by use of a capture oligomer via target capture that utilizes magnetic microparticles. The capture oligomer contains a sequence complementary to a specific region of the target molecule as well as a string of deoxyadenosine residues. During the hybridization step, the sequence specific region of the capture oligomer binds to a specific region of the target molecule. The capture oligomer:target complex is then captured out of solution by decreasing the temperature of the reaction to room temperature. This temperature reduction allows hybridization to occur between the deoxyadenosine region on the capture oligomer and the poly-deoxythymidine molecules that are covalently attached to the magnetic particles. The microparticles, including the captured target molecule bound to them, are pulled to the side of the reaction vessel using magnets and the supernatant is aspirated. The particles are washed to remove residual specimen matrix that may contain amplification reaction inhibitors. After the target capture steps are completed, the specimens are ready for amplification.

Target amplification assays are based on the ability of complementary oligonucleotide primers to specifically anneal and allow enzymatic amplification of the target nucleic acid strands. The Hologic TMA reaction replicates a specific region of the 16S rRNA from CT via DNA intermediates. A unique set of primers is used for the target molecule. Detection of the rRNA amplification product sequences (amplicon) is achieved using nucleic acid hybridization. A single-stranded chemiluminescent DNA probe, which is complementary to a region of the target amplicon, is labeled with an acridinium ester molecule. The labeled DNA probe combines with amplicon to form stable RNA:DNA hybrids. The Selection Reagent differentiates hybridized from unhybridized probe, eliminating the generation of signal from unhybridized probe. During the detection step, light emitted from the labeled RNA:DNA hybrids is measured as photon signals in a luminometer, and are reported as Relative Light Units (RLU).

Summary of Safety and Performance

The SSP (Summary of Safety and Performance) is available in the European database on medical devices (Eudamed), where it is linked to the device identifiers (Basic UDI-DI). To locate the SSP for Aptima CT assay, refer to the Basic Unique Device Identifier (BUDI): 54200455DIAGAPTCTRA.

Warnings and Precautions

- A. For *in vitro* diagnostic use.
- B. For professional use.
- C. To reduce the risk of invalid results, carefully read the entire package insert and the *Panther/Panther Fusion® System Operator's Manual* prior to performing the assay.
- D. Only personnel adequately trained in the use of the Aptima CT assay and in handling potentially infectious materials should perform this procedure. If a spill occurs, immediately disinfect following appropriate site procedures.
- E. For additional specific warnings, precautions and procedures to control contamination for the Panther/Panther Fusion system, consult the *Panther/Panther Fusion System Operator's Manual*.

Laboratory Related

- F. Use only supplied or specified disposable laboratory ware.
- G. Use routine laboratory precautions. Do not eat, drink or smoke in designated work areas. Wear disposable, powderless gloves, protective eye wear, and laboratory coats when handling specimens and kit reagents. Wash hands thoroughly after handling specimens and kit reagents.
- H. **Warning: Irritant and Corrosive:** Avoid contact of Auto Detect 2 with skin, eyes and mucous membranes. If this fluid comes into contact with skin or eyes, wash with water. If this fluid spills, dilute the spill with water before wiping dry.
- I. Work surfaces, pipettes, and other equipment must be regularly decontaminated with 2.5% to 3.5% (0.35 M to 0.5 M) sodium hypochlorite solution.
- J. Dispose of all materials that have come in contact with specimens and reagents in accordance with applicable national, international, and regional regulations.
- K. Use good standard practices for molecular laboratories including environmental monitoring. See *Procedural Notes* for suggested Lab Contamination Monitoring Protocol for the Panther system.

Specimen Related



- L. This assay has been tested using endocervical and male urethral swab specimens, PreservCyt solution Pap specimens, vaginal swab specimens, and female and male urine specimens only. Performance with specimens other than those specified under *Specimen Collection and Storage* has not been evaluated.
Laboratories may validate other collection devices (14, 16).
- M. Expiration dates listed on the collection kits pertain to the collection site and not the testing facility. Samples collected any time prior to the expiration date of the collection kit, and transported and stored in accordance with the package insert, are valid for testing even if the expiration date on the collection tube has passed.

- N. The PreservCyt solution has been validated as an alternative medium for testing with the Aptima CT assay. PreservCyt solution Pap specimens processed using instruments other than the ThinPrep® Processor have not been evaluated for use.
- O. After urine has been added in the urine transport tube, the liquid level must fall between the two black indicator lines on the tube label. Otherwise, the specimen must be rejected.
- P. Maintain proper storage conditions during specimen shipping to ensure the integrity of the specimen. Specimen stability under shipping conditions other than those recommended has not been evaluated.
- Q. Specimens may be infectious. Use Universal Precautions when performing this assay. Proper handling and disposal methods should be established by the laboratory director. Only personnel adequately trained in handling infectious materials should be permitted to perform this diagnostic procedure.
- R. Avoid cross-contamination during the specimen handling steps. Specimens can contain extremely high levels of organisms. Ensure that specimen containers do not contact one another, and discard used materials without passing them over open containers. Change gloves if they come in contact with specimen.
- S. If the lab receives a swab specimen transport tube with no swab, two swabs, a cleaning swab, or a swab not supplied by Hologic, the specimen must be rejected. Prior to rejecting a swab transport tube with no swab, verify that it is not an Aptima® Specimen Transfer Tube as this specimen transport tube will not contain a swab.
- T. For PreservCyt solution Pap specimens, collect according to the manufacturer's instructions. Aliquots subsequently removed from the PreservCyt vial for testing by the Aptima CT assay should be processed using only the Aptima® Specimen Transfer Kit.
- U. Upon piercing, liquid can discharge from Aptima transport tube caps under certain conditions. Follow instructions in the *Panther System Test Procedure* to prevent this occurrence.

Assay Related

- V. Do not use this kit after its expiration date.
- W. Cap and store reagents at the specified temperatures. The performance of the assay may be affected by use of improperly stored reagents. See *Reagent Storage and Handling Requirements* and *Panther System Test Procedure* for more information.
- X. Do not combine any assay reagents or fluids without specific instruction. Do not top off reagents or fluids. The Panther system verifies reagent levels.
- Y. Avoid microbial and ribonuclease contamination of reagents.
- Z. Do not interchange, mix, or combine assay reagents from kits with different lot numbers. Aptima controls and assay fluids can be from different lot numbers.
- AA. Some reagents in this kit are labeled with hazard information.

Note: Hazard communication reflects the EU Safety Data Sheets (SDS) classifications. For hazard communication information specific to your region, refer to the region specific SDS on the Safety Data Sheet Library at www.hologicds.com. For more information on the symbols, refer to the symbol legend on <https://www.hologic.com/package-inserts>.

EU Hazard Information	
—	Amplification Reagent <i>HEPES 25 - 30%</i> — H412 - Harmful to aquatic life with long lasting effects. P273 - Avoid release to the environment. P501 - Dispose of contents/container to an approved waste disposal plant.
—	Enzyme Reagent <i>HEPES 1 - 5%</i> <i>TRITON X-100 1 - 5%</i> — H412 - Harmful to aquatic life with long lasting effects. P273 - Avoid release to the environment. P501 - Dispose of contents/container to an approved waste disposal plant.
—	Probe Reagent <i>LAURYL SULFATE LITHIUM SALT 35 - 40%</i> <i>SUCCINIC ACID 10 - 15%</i> — H412 - Harmful to aquatic life with long lasting effects. P273 - Avoid release to the environment. P501 - Dispose of contents/container to an approved waste disposal plant.
—	Enzyme Reconstitution Solution <i>GLYCEROL 20 - 25%</i> <i>TRITON X-100 5 - 10%</i> <i>HEPES 1 - 5%</i> — H412 - Harmful to aquatic life. P273 - Avoid release to the environment. P501 - Dispose of contents/container to an approved waste disposal plant.
 	Selection Reagent <i>BORIC ACID 0 - 10%</i> <i>TRITON X-100 0 - 10%</i> <i>SODIUM HYDROXIDE 0 - 10%</i> Danger H315 - Causes skin irritation. H360FD - May damage fertility. May damage the unborn child. P264 - Wash face, hands and exposed skin thoroughly after handling. P280 - Wear protective gloves/protective clothing/eye protection/face protection. P302 + P352 - IF ON SKIN: Wash with plenty of water and soap. P321 - Specific treatment (see supplemental first aid instructions on the SDS). P332 + P313 - If skin irritation occurs: Get medical advice/attention. P362 + P364 - Take off contaminated clothing and wash it before reuse. P201 - Obtain special instructions before use. P202 - Do not handle until all safety precautions have been read and understood. P308 + P313 - IF exposed or concerned: Get medical advice/attention. P405 - Store locked up. P501 - Dispose of contents/container to an approved waste disposal plant.

Target Capture Reagent*HEPES 5 - 10%**EDTA 1 - 5%**LITHIUM HYDROXIDE, MONOHYDRATE 1 - 5%*

—

H401 - Toxic to aquatic life.

H412 - Harmful to aquatic life with long lasting effects.

P273 - Avoid release to the environment.

P501 - Dispose of contents/container to an approved waste disposal plant.

Reagent Storage and Handling Requirements

A. The following table shows the storage conditions and stability for reagents and controls:

Reagent	Unopened Storage	Open Kit (Reconstituted)	
		Storage	Stability
Amplification Reagent	2°C to 8°C		
Enzyme Reagent	2°C to 8°C		
Probe Reagent	2°C to 8°C		
Target Capture Reagent B	2°C to 8°C		
Amplification Reconstitution Solution	2°C to 30°C	2°C to 8°C	60 days
Enzyme Reconstitution Solution	2°C to 30°C	2°C to 8°C	60 days
Probe Reconstitution Solution	2°C to 30°C	2°C to 8°C	60 days
Selection Reagent	2°C to 30°C	2°C to 30°C	
Target Capture Reagent	15°C to 30°C	15°C to 30°C	60 days
Positive Control, CT / Negative Control GC	2°C to 8°C		Single Use Vial
Positive Control, GC/ Negative Control CT	2°C to 8°C		Single Use Vial

- B. If the Selection Reagent is stored refrigerated, let it come to room temperature before placing on the Panther system.
- C. Working Target Capture Reagent (wTCR) is stable for 60 days when stored at 15°C to 30°C. Do not refrigerate.
- D. After reconstitution, the Enzyme Reagent, Amplification Reagent, and Probe Reagent are stable for 60 days when stored at 2°C to 8°C.
- E. Discard any unused reconstituted reagents and wTCR after 60 days or after the Master Lot expiration date, whichever comes first.
- F. Avoid cross-contamination during reagent handling and storage. Recap all reconstituted reagents with new reagent caps each time prior to storage.
- G. Controls are stable until the date indicated on the vials.
- H. Reagents stored on-board the Panther system have 72 hours of on-board stability.
- I. The Probe Reagent and Reconstituted Probe Reagent are photosensitive. Store the reagents protected from light.
- J. Upon warming to room temperature, some control tubes may appear cloudy or contain precipitates. Cloudiness or precipitation associated with controls does not affect control performance. The controls may be used whether they are clear or cloudy/precipitated. If clear controls are desired, solubilization may be expedited by incubating them at the upper end of the room temperature range (15°C to 30°C).
- K. Do not freeze the reagents.

Specimen Collection and Storage

The Aptima CT assay is designed to detect the presence of CT in clinician-collected endocervical, vaginal and male urethral swab specimens, patient-collected vaginal swab specimens, female and male urine specimens, and PreservCyt solution Pap specimens.

Performance with specimens other than those collected with the following specimen collection kits has not been evaluated:

- Aptima Multitest Swab Specimen Collection Kit
- Aptima Urine Collection Kit for Male and Female Urine Specimens
- Aptima Unisex Swab Specimen Collection Kit for Endocervical and Male Urethral Swab Specimens
- Aptima Specimen Transfer Kit (for use with gynecologic samples collected in PreservCyt solution)

A. Instructions for Collection

Refer to the appropriate specimen collection kit package insert for collection instructions.

B. Specimen Transport and Storage Before Testing

1. Swab Specimens

- a. After collection, transport and store the swab in the swab specimen transport tube at 2°C to 30°C until tested. Specimens must be assayed with the Aptima CT assay within 60 days of collection. If longer storage is needed, freeze swab specimens in the swab specimen transport tube within 7 days of collection at –20°C to –70°C to allow testing up to 12 months after collection (see *Specimen Stability Studies*).

2. Urine Specimens

- a. Maintain urine specimen at 2°C to 30°C after collection and transfer to the Aptima urine specimen transport tube within 24 hours of collection. Transport to the lab in the primary collection container or the transport tube at 2°C to 30°C. Store at 2°C to 30°C and test the processed urine specimens with the Aptima CT assay within 30 days of collection.
- b. If longer storage is needed, freeze urine specimens in the Aptima urine specimen transport tube within 7 days of collection at –20°C to –70°C to allow testing up to 12 months after collection (see *Specimen Stability Studies*).

3. PreservCyt Solution Pap Specimens

- a. PreservCyt solution Pap specimens intended for CT testing must be processed for cytology and/or transferred to an Aptima specimen transfer tube within 30 days of collection when stored at 2°C to 30°C (see *Specimen Stability Studies*).
- b. If the ThinPrep aliquot removal procedure will be used, refer to the *ThinPrep Processor Operator's Manual* for instructions on aliquot removal. Transfer 1 mL of the removed aliquot into an Aptima specimen transfer tube according to the instructions in the Aptima Specimen Transfer Kit and Specimen Transfer Solution package insert.
- c. If testing the specimen after processing using the ThinPrep processor, process the PreservCyt solution Pap specimen in accordance with the *ThinPrep Processor Operator's Manual* and the Aptima Specimen Transfer Kit and Specimen Transfer Solution package insert. Transfer 1.0 mL of the fluid remaining in the PreservCyt solution vial into an Aptima specimen transfer tube according to the instructions in the Aptima Specimen Transfer Kit and Specimen Transfer Solution package insert.
- d. Once the PreservCyt solution Pap specimen is transferred to the Aptima specimen transfer tube, the specimen must be assayed with the Aptima CT assay within 30 days when stored at 2°C to 8°C or 14 days when stored at 15°C to 30°C. If longer storage is needed, freeze specimen within 7 days of transfer to the

Aptima specimen transfer tube at –20°C to –70°C to allow testing up to 12 months after transfer (see *Specimen Stability Studies*).

C. Specimen Storage After Testing

1. Specimens that have been assayed must be stored upright in a rack.
2. The specimen transport tubes should be covered with a new, clean plastic film or foil barrier.
3. If assayed samples need to be frozen or shipped, remove the penetrable caps and place new non-penetrable or penetrable caps on the specimen transport tubes. If specimens need to be shipped for testing at another facility, recommended temperatures must be maintained. Prior to uncapping previously tested and recapped samples, specimen transport tubes must be centrifuged for 5 minutes at 420 RCF (Relative Centrifugal Force) to bring all of the liquid down to the bottom of the tube.

Avoid splashing and cross-contamination.

Note: *Specimens must be shipped in accordance with applicable national and international transportation regulations.*

Panther System

Reagents for the Aptima CT assay are listed below for the Panther system. Reagent Identification Symbols are also listed next to the reagent name.

Reagents and Materials Provided

Aptima Chlamydia trachomatis Assay Kit, 100 tests (2 boxes and 1 Controls kit)
(Cat. No. 302925)

Aptima Chlamydia trachomatis Assay Refrigerated Box (Box 1 of 2)
(store at 2°C to 8°C upon receipt)

Symbol	Component	Quantity
A	Amplification Reagent <i>Non-infectious nucleic acids dried in buffered solution containing < 5% bulking agent.</i>	1 vial
E	Enzyme Reagent <i>Reverse transcriptase and RNA polymerase dried in HEPES buffered solution containing < 10% bulking reagent.</i>	1 vial
P	Probe Reagent <i>Non-infectious chemiluminescent DNA probes dried in succinate buffered solution containing < 5% detergent.</i>	1 vial
TCR-B	Target Capture Reagent B <i>Non-infectious nucleic acids in a buffered solution containing < 5% detergent.</i>	1 x 0.30 mL

Aptima Chlamydia trachomatis Assay Room Temperature Box (Box 2 of 2)
(store at 15°C to 30°C upon receipt)

Symbol	Component	Quantity
AR	Amplification Reconstitution Solution <i>Aqueous solution containing preservatives.</i>	1 x 11.9 mL
ER	Enzyme Reconstitution Solution <i>HEPES buffered solution containing a surfactant and glycerol.</i>	1 x 6.3 mL
PR	Probe Reconstitution Solution <i>Succinate buffered solution containing < 5% detergent.</i>	1 x 15.2 mL
S	Selection Reagent <i>600 mM borate buffered solution containing surfactant.</i>	1 x 43.0 mL
TCR	Target Capture Reagent <i>Buffered salt solution containing solid phase and capture oligomers.</i>	1 x 26.0 mL
	Reconstitution Collars	3
	Master Lot Barcode Sheet	1 sheet

Aptima Controls Kit
(store at 2°C to 8°C upon receipt)

Symbol	Component	Quantity
PCT/NGC	Positive Control, CT / Negative Control, GC <i>Non-infectious CT nucleic acid in a buffered solution containing < 5% detergent. Each 400 µL sample contains the estimated rRNA equivalent of 1 CT IFU (5 fg/assay*).</i>	5 x 1.7 mL
PGC/NCT	Positive Control, GC / Negative Control, CT <i>Non-infectious GC nucleic acid in a buffered solution containing < 5% detergent. Each 400 µL sample contains the estimated rRNA equivalent of 50 GC cells (250 fg/assay*).</i>	5 x 1.7 mL

*The rRNA equivalents were calculated based on the genome size and estimated DNA:RNA ratio/cell of each organism.

Materials Required But Available Separately

Note: Materials available from Hologic have catalog numbers listed, unless otherwise specified.

	<u>Cat. No.</u>
Panther System	303095
Panther Fusion System	PRD-04172
Panther System, Continuous Fluid and Waste (Panther Plus)	PRD-06067
Aptima Assay Fluids Kit <i>(Aptima Wash Solution, Aptima Buffer for Deactivation Fluid, and Aptima Oil Reagent)</i>	303014 (1000 tests)
Aptima Auto Detect Kit	303013 (1000 tests)
Multi-tube units (MTUs)	104772-02
Panther Waste Bag Kit	902731
Panther Waste Bin Cover	504405
Or Panther Run Kit <i>contains MTUs, waste bags, waste bin covers, assay fluids, and auto detects</i>	303096 (5000 tests)
Tips, 1000 µL, filtered, conductive, liquid sensing, and disposable	901121 (10612513 Tecan) 903031 (10612513 Tecan)
<i>Not all products are available in all regions. Contact your representative for region-specific information.</i>	MME-04134 (30180117 Tecan) MME-04128
Aptima Specimen Transfer Kit <i>for use with specimens in PreservCyt Solution</i>	301154C
Aptima Specimen Transfer Kit — printable <i>for use with specimens in PreservCyt Solution</i>	PRD-05110
Aptima Multitest Swab Specimen Collection Kit	PRD-03546
Aptima Unisex Swab Specimen Collection Kit for Endocervical and Male Urethral Swab Specimens	301041
Aptima Urine Specimen Collection Kit for Male and Female Urine Specimens	301040
Aptima Urine Specimen Transport Tubes for Male and Female Urine Specimens	105575

Bleach, 5% to 8.25% (0.7 M to 1.16 M) sodium hypochlorite solution	—
Disposable gloves	—
Aptima penetrable caps	105668
Replacement non-penetrable caps	103036A
Replacement caps for the 100-test kits	—
Amplification, Enzyme, and Probe reagent reconstitution solutions	CL0041 (100 caps)
TCR and Selection reagent	501604 (100 caps)

Optional Materials

	<u>Cat. No.</u>
Aptima Controls Kit	301110
Hologic Bleach Enhancer for Cleaning <i>for routine cleaning of surfaces and equipment</i>	302101
Tube Rocker	—

Panther System Test Procedure

Note: See the *Panther/Panther Fusion System Operator's Manual* for additional Panther system procedural information.

A. Work Area Preparation

1. Clean work surfaces where reagents and samples will be prepared. Wipe down work surfaces with 2.5% to 3.5% (0.35 M to 0.5 M) sodium hypochlorite solution. Allow the sodium hypochlorite solution to contact surfaces for at least 1 minute and then follow with a water rinse. Do not allow the sodium hypochlorite solution to dry. Cover the bench surface on which the reagents and samples will be prepared with clean, plastic-backed absorbent laboratory bench covers.

B. Reagent Reconstitution/Preparation of a New Kit

Note: Reagent reconstitution should be performed prior to beginning any work on the Panther system.

1. To reconstitute Amplification, Enzyme, and Probe Reagents, combine the bottles of lyophilized reagent with the reconstitution solution. If refrigerated, allow the reconstitution solutions to reach room temperature before use.
 - a. Pair each reconstitution solution with its lyophilized reagent. Ensure that the reconstitution solution and reagent have matching label colors before attaching the reconstitution collar.
 - b. Check the lot numbers on the Master Lot Barcode Sheet to ensure that the appropriate reagents are paired.
 - c. Open the lyophilized reagent vial and firmly insert the notched end of the reconstitution collar into the vial opening (Figure 1, Step 1).
 - d. Open the matching reconstitution solution, and set the cap on a clean, covered work surface.
 - e. While holding the reconstitution solution bottle on the bench, firmly insert the other end of the reconstitution collar into the bottle opening (Figure 1, Step 2).

- f. Slowly invert the assembled bottles. Allow the solution to drain from the bottle into the glass vial (Figure 1, Step 3).
- g. Gently swirl the solution in the bottle to mix. Avoid creating foam while swirling the bottle. (Figure 1, Step 4).
- h. Wait for the lyophilized reagent to go into solution, then invert the assembled bottles again, tilting at a 45° angle to minimize foaming (Figure 1, Step 5). Allow all of the liquid to drain back into the plastic bottle.
- i. Remove the reconstitution collar and glass vial (Figure 1, Step 6).
- j. Recap the plastic bottle. Record operator initials and the reconstitution date on the label (Figure 1, Step 7).
- k. Discard the reconstitution collar and glass vial (Figure 1, Step 8).

Option: Additional mixing of the Amplification, Enzyme and Probe Reagents is allowed by placing recapped plastic bottles on a tube rocker set at a moderate speed and tilt for a minimum of 5 minutes. Ensure reagents are thoroughly mixed.

Warning: Avoid creating foam when reconstituting reagents. Foam compromises the level-sensing in the Panther system.

Warning: Adequate mixing of the reagents is necessary to achieve expected assay results.




Figure 1. Reagent Reconstitution Process

2. Prepare the Working Target Capture Reagent (wTCR)
 - a. Pair the appropriate bottles of TCR and TCR-B.
 - b. Check the reagent lot numbers on the Master Lot Barcode Sheet to make sure that the appropriate reagents in the kit are paired.
 - c. Open the bottle of TCR, and set the cap on a clean, covered work surface.
 - d. Open the bottle of TCR-B and pour the entire contents into the bottle of TCR. Expect a small amount of liquid to remain in the TCR-B bottle.
 - e. Cap the bottle of TCR and gently swirl the solution to mix the contents. Avoid creating foam during this step.
 - f. Record operator initials and the current date on the label.
 - g. Discard the TCR-B bottle and cap.

3. Prepare Selection Reagent
 - a. Check the lot number on the reagent bottle to make sure that it matches the lot number on the Master Lot Barcode Sheet.
 - b. Record operator initials and the current date on the label.

Note: *Thoroughly mix by gently inverting all reagents prior to loading on the system. Avoid creating foam during inversion of reagents.*

C. Reagent Preparation for Previously Reconstituted Reagents

1. Previously reconstituted Amplification, Enzyme, and Probe Reagents must reach room temperature (15°C to 30°C) prior to the start of the assay.

Option: The reconstituted Amplification, Enzyme, and Probe Reagent capped plastic bottles may be placed on a tube rocker set at a moderate speed and tilt for a minimum of 25 minutes to ensure reagents reach room temperature and are thoroughly mixed.

2. If reconstituted Probe Reagent contains precipitate that does not return to solution at room temperature, heat the capped bottle at a temperature that does not exceed 62°C for 1 to 2 minutes. After this heat step, the Probe Reagent may be used even if residual precipitate remains. Mix Probe Reagent by inversion, being careful not to induce foam, prior to loading onto the system.
3. Thoroughly mix each reagent by gently inverting prior to loading on the system. Avoid creating foam during inversion of reagents.
4. Do not top off reagent bottles. The Panther system will recognize and reject bottles that have been topped off.

Warning: *Adequate mixing of the reagents is necessary to achieve expected assay results.*

D. Specimen Handling

1. Allow the controls and specimens to reach room temperature prior to processing.
2. Do not vortex specimens.
3. Visually confirm that each specimen tube meets one of the following criteria:
 - a. The presence of a single pink Aptima collection swab in a multitest swab specimen transport tube.
 - b. A final volume of urine between the black fill lines of a urine specimen transport tube.
 - c. The presence of a single blue Aptima collection swab in a unisex swab specimen transport tube.
 - d. The absence of a swab in the Aptima specimen transport tube for PreservCyt solution Pap specimens.
4. Inspect specimen tubes before loading into the rack:
 - a. If a specimen tube contains bubbles in the space between the liquid and the cap, centrifuge the tube for 5 minutes at 420 RCF to eliminate the bubbles.
 - b. If a specimen tube has a lower volume than typically observed when collection instructions have been followed, centrifuge the tube for 5 minutes at 420 RCF to ensure that no liquid is in the cap.

- c. If the liquid level in a urine specimen tube is not between the two black indicator lines on the label, the specimen must be rejected. Do not pierce an overfilled tube.
- d. If a urine specimen tube contains precipitate, heat the specimen at 37°C for up to 5 minutes. If the precipitate does not go back into solution, visually ensure that the precipitate does not prevent delivery of the specimen.

Note: Failure to follow Steps 4a–c may result in liquid discharge from the specimen tube cap.

Note: Up to 4 separate aliquots can be tested from each specimen tube. Attempts to pipette more than 4 aliquots from the specimen tube can lead to processing errors.

E. System Preparation

1. Set up the system according to the instructions in the *Panther/Panther Fusion System Operator's Manual* and *Procedural Notes*. Make sure that the appropriately sized reagent racks and TCR adapters are used.
2. Load samples.

Procedural Notes

A. Controls

1. To work properly with the Aptima assay software for the Panther system, one pair of controls is required. The Positive Control, CT / Negative Control, GC and the Positive Control, GC / Negative Control CT tubes can be loaded in any rack position or in any Sample Bay Lane on the Panther system. Patient specimen pipetting will begin when one of the following two conditions has been met:
 - a. A pair of controls is currently being processed by the system.
 - b. Valid results for the controls are registered on the system.
2. Once the control tubes have been pipetted and are processing for a specific reagent kit, patient specimens can be run with the associated assay reagent kit up to 24 hours **unless**:
 - a. Control results are invalid.
 - b. The associated assay reagent kit is removed from the system.
 - c. The associated assay reagent kit has exceeded stability limits.
3. Each Aptima control tube can be tested once. Attempts to pipette more than once from the tube can lead to processing errors.

B. Temperature

Room temperature is defined as 15°C to 30°C.

C. Glove Powder

As in any reagent system, excess powder on some gloves may cause contamination of opened tubes. Powderless gloves are recommended.

D. Lab Contamination Monitoring Protocol for the Panther System

There are many laboratory-specific factors that may contribute to contamination, including testing volume, workflow, disease prevalence and various other laboratory activities. These factors should be taken into consideration when contamination monitoring

frequency is being established. Intervals for contamination monitoring should be established based on each laboratory's practices and procedures.

To monitor for laboratory contamination, the following procedure may be performed using the Aptima unisex swab specimen collection kit for endocervical and male urethral swab specimens:

1. Label swab transport tubes with numbers corresponding to the areas to be tested.
2. Remove the specimen collection swab (blue shaft swab with green printing) from its packaging, wet the swab in the Specimen Transport Medium (STM), and swab the designated area using a circular motion.
3. Immediately insert the swab into transport tube.
4. Carefully break the swab shaft at the score line; use care to avoid splashing of the contents.
5. Recap the swab transport tube tightly.
6. Repeat Steps 2 to 5 for each area to be swabbed.

If the results are CT positive or equivocal, see *Test Interpretation — QC/Patient Results*. For additional Panther system-specific contamination monitoring information, contact Hologic Technical Support.

Test Interpretation — QC/Patient Results

A. Test Interpretation

Assay test results are automatically interpreted by the Aptima Assay software using the CT protocol. A test result may be negative, equivocal, positive, or invalid as determined by total RLU in the detection step (see below). A test result may be invalid due to RLU values outside the normal expected ranges. Initial equivocal and invalid test results should be retested.

Test Interpretation	Total RLU (x1000)
Negative	0* to < 50
Equivocal	50 to < 100
Low RLU Positive ^{1,2}	100 to < 5,000
Positive ^{1,2}	5,000 to < 12,000
Invalid	0* or > 12,000

*A zero (0 x 1000) RLU result on the run report represents a value between zero and 999 RLU. RLU values less than 690 on the Panther System will be reported as invalid.

¹Refer to Table 3 for RLU distribution of results. The magnitude of RLU is not indicative of the level of organism in the specimen.

²In the low positive range, data suggest positive results should be interpreted carefully, with the understanding that the likelihood of a false positive may be higher than a true positive.

B. Quality Control Results and Acceptability

The Negative Control for CT, which is labeled “CONTROL + GC PGC / CONTROL – CT NCT,” and the Positive Control for CT, which is labeled “CONTROL + CT PCT / CONTROL – GC NGC,” act as controls for the target capture, amplification, and detection steps of the assay. In accordance with guidelines or requirements of regional regulations or accrediting organizations, additional controls for cell lysis and RNA stabilization may be included. The Negative Control for CT, which is labeled “CONTROL + GC PGC / CONTROL – CT NCT,” contains non-infectious GC rRNA. If desired, additional controls can be ordered as a kit. See *Optional Materials*. Correct preparation of specimens is confirmed visually by the presence of a single Aptima collection swab in a swab specimen transport tube, a final volume of urine in between the black fill lines of a urine specimen transport tube, or the absence of a swab in an Aptima specimen transfer tube for liquid Pap specimens.

The Positive Controls must produce the following test results:

Control	Total RLU (x1000)	CT Result
Positive Control, GC/ Negative Control, CT	0* and < 50	Negative
Positive Control, CT/ Negative Control, GC	≥ 100 and < 12,000	Positive

*A zero (0 x 1000) RLU result on the run report represents a value between zero and 999 RLU. RLU values less than 690 on the Panther System will be reported as invalid.

1. The Aptima assay software automatically evaluates the controls according to the above criteria and will report the Run Status as PASS if the run control criteria are met, and FAIL if the run control criteria are not met.
2. If the Run Status is FAIL, all test results in the same run are invalid and must not be reported.
3. Each laboratory should implement appropriate control procedures to satisfy the requirements of CLIA regulations.
4. Negative controls may not be effective in monitoring random carryover. See *Analytical Performance* for results from a high-target analytical carryover study that was performed to demonstrate control of carryover on the Panther system.

C. Specimen Preparation Control (optional)

The Negative Control for CT, which is labeled “CONTROL + GC PGC / CONTROL – CT NCT,” and the Positive Control for CT, which is labeled “CONTROL + CT PCT / CONTROL – GC NGC,” act as controls for the target capture, amplification, and detection steps of the assay and must be included in each assay run. If desired, controls for cell lysis and RNA stabilization can be tested in accordance with the requirements of appropriate accrediting organizations or individual laboratory procedures. Known positive specimens can serve as controls by being prepared and tested in conjunction with unknown specimens. Specimens used as preparation controls must be stored, handled, and tested according to the package insert. Specimen preparation controls should be interpreted in the same manner as described for patient test specimens. See *Test Interpretation — QC/Patient Results, Patient Test Results*.

D. Patient Test Results

1. If the controls in any run do not yield the expected results, test results on patient specimens in the same run must not be reported.
2. Swab, urine, and PreservCyt solution Pap specimen results. See *Notes* below.
 - a. Initial results

CT Pos*	Positive for CT rRNA.
CT Neg	Presumed negative for CT rRNA.
CT Equiv	Sample should be retested.
Invalid	Sample should be retested.

b. Retest results

CT Pos*	Positive for CT rRNA.
CT Neg	Presumed negative for CT rRNA.
CT Equiv	Indeterminate, a new specimen should be collected.
Invalid	Indeterminate, a new specimen should be collected.

*Low RLU Positive specimen results are included in this category. See *Test Interpretation — QC/Patient Results* above.

Notes

- The first valid, non-equivocal result for each analyte is the result that should be reported.
- Careful consideration of performance data is recommended for interpreting Aptima CT test results for asymptomatic individuals or any individuals in low prevalence populations.
- A negative result does not preclude the presence of a CT infection because results are dependent on adequate specimen collection, absence of inhibitors, and sufficient rRNA to be detected. Test results may be affected by improper specimen collection, improper specimen storage, technical error, specimen mix-up, or target levels below the assay limit of detection.
- Testing of an endocervical specimen is recommended for female patients who are clinically suspected of having a chlamydial or gonococcal infection. If both a Pap and endocervical swab are collected, the PreservCyt solution Pap specimen must be collected before the endocervical swab specimen.

Limitations

- A. Use of this assay is limited to personnel who have been trained in the procedure. Failure to follow the instructions given in this package insert may result in erroneous results.
- B. The effects of tampon use, douching, and specimen collection variables have not been assessed for their impact on the detection of CT.
- C. The presence of mucus in endocervical specimens does not interfere with the detection of CT by the Aptima CT assay. However, to ensure collection of cells infected with CT, columnar epithelial cells lining the endocervix should be sampled. If excess mucus is not removed, sampling of these cells is not ensured.
- D. Urine, vaginal swab, and PreservCyt solution Pap specimen sampling is not designed to replace cervical exams and endocervical specimens for diagnosis of female urogenital infections. Patients may have cervicitis, urethritis, urinary tract infections, or vaginal infections due to other causes or concurrent infections with other agents.
- E. The Aptima CT assay is not intended for the evaluation of suspected sexual abuse or for other medico-legal indications.
- F. Reliable results are dependent on adequate specimen collection. Because the transport system used for this assay does not permit microscopic assessment of specimen adequacy, proper specimen collection techniques are necessary. Refer to package insert of the appropriate Aptima specimen collection kit.
- G. Therapeutic failure or success cannot be determined with the Aptima CT assay since nucleic acid may persist following appropriate antimicrobial therapy.
- H. Results from the Aptima CT assay should be interpreted in conjunction with other laboratory and clinical data available to the clinician.
- I. A negative result does not preclude a possible infection because results are dependent on adequate specimen collection. Test results may be affected by improper specimen collection, technical error, specimen mix-up, or target levels below the assay limit of detection.
- J. The Aptima CT assay provides qualitative results. Therefore, a correlation cannot be drawn between the magnitude of a positive assay signal and the number of organisms in a specimen.
- K. For the vaginal swab, endocervical swab, male urethral swab and urine specimen clinical studies, performance for detecting CT is derived from high prevalence populations. Positive results in low prevalence populations should be interpreted carefully with the understanding that the likelihood of a false positive may be higher than a true positive.
- L. For the PreservCyt solution Pap specimen clinical studies, the Aptima CT assay performance for detecting CT is derived primarily from low prevalence populations. Nonetheless, positive results in low prevalence populations should be interpreted carefully with the understanding that the likelihood of a false positive may be higher than a true positive.
- M. Performance of the Aptima specimen transfer kit was not evaluated for testing the same PreservCyt solution Pap specimen both before and after ThinPrep Pap processing.

- N. PreservCyt solution Pap specimens processed with instruments other than the ThinPrep processor have not been evaluated.
- O. Patient-collected vaginal swab specimens are an option for screening women when a pelvic exam is not otherwise indicated.
- P. The patient-collected vaginal swab specimen application is limited to clinical settings where support/counseling is available to explain the procedures and precautions.
- Q. The performance of the Aptima CT assay has not been evaluated in adolescents less than 14 years of age.
- R. The performance of the Panther system has not been evaluated at altitudes above 2000 m (6561 feet).
- S. There is no evidence of degradation of nucleic acids in PreservCyt solution. If a PreservCyt solution Pap specimen has small numbers of CT cellular material, uneven distribution of this cellular material may occur. Also, when compared to direct sampling with the Aptima Swab Transport Media, the additional volume of PreservCyt solution results in greater dilution of the sample material. These factors may affect the ability to detect small numbers of organisms in the collected material. If negative results from the specimen do not fit with the clinical impression, a new specimen may be necessary.
- T. Customers must independently validate an LIS transfer process.

Clinical Study Results

The performance of the Aptima CT assay was established in three multi-center clinical investigations conducted in North America. The first investigation established the sensitivity, specificity, and predictive values of the Aptima CT assay using clinician-collected endocervical, vaginal, and male urethral swab specimens, patient-collected vaginal swab specimens, and male and female urine specimens. The second clinical investigation established the sensitivity, specificity, and predictive values of the Aptima CT assay using PreservCyt solution (component of the ThinPrep® System).

The initial two clinical investigations to establish the sensitivity, specificity and predictive values of the Aptima CT assay were completed using a semi-automated DTS® System. The assay was then migrated to a fully automated Tigris® DTS System (without any changes to assay formulation) using clinical comparability studies. Lastly, clinical comparability studies were used to migrate the Aptima CT assay from the Tigris DTS system to its current system of use, the Panther system. Data from the initial studies using the DTS or Tigris DTS systems are shown herein to support establishment of the assay performance, although current use of these systems is no longer supported by the manufacturer.

In the third clinical investigation, the clinical performance of the Aptima CT assay was evaluated in sexually active male and female subjects at least 14 years of age with or without symptoms of STIs. This study evaluated patient-collected vaginal swab and urine specimens tested using the Panther system.

Expected Values

Prevalence

The prevalence of CT in patient populations depends on risk factors such as age, gender, the presence of symptoms, the type of clinic, and the test method. A summary of the positivity of CT, by specimen type as determined by the Aptima CT assay on the DTS system is shown in Tables 1a and 1b for two multi-center clinical investigations by clinical site and overall. Table 1c summarizes positivity of CT for the Aptima CT assay on the Panther system as determined by an additional multicenter clinical investigation.

Table 1a: Positivity of *C. trachomatis* by Clinical Site and Overall as Determined by Aptima CT Assay Results on the DTS System

Site	% (#positive / #tested)											
	MS		MU		FS		FU		PVS		CVS	
1	27.0	(68/252)	25.0	(63/252)	16.5	(38/230)	17.0	(39/229)	19.2	(42/219)	19.1	(44/230)
2	27.7	(98/354)	26.6	(94/354)	35.0	(70/200)	26.5	(53/200)	30.8	(61/198)	33.0	(66/200)
3	25.0	(1/4)	25.0	(1/4)	11.4	(13/114)	8.8	(10/113)	10.8	(12/111)	11.5	(13/113)
4	N/A	N/A	N/A	N/A	11.6	(31/267)	8.1	(22/271)	9.3	(25/268)	12.2	(33/270)
5	8.0	(16/200)	8.0	(16/200)	9.0	(18/199)	7.5	(15/199)	8.0	(16/199)	10.1	(20/199)
6	22.7	(69/304)	20.0	(61/305)	14.3	(42/294)	13.2	(39/295)	15.2	(44/290)	16.2	(48/296)
7	5.8	(12/207)	6.3	(13/207)	7.8	(8/102)	9.8	(10/102)	12.7	(13/102)	8.8	(9/102)
8	N/A	N/A	N/A	N/A	8.2	(4/49)	6.1	(3/49)	12.5	(6/48)	7.8	(4/51)
All	20.0	(264/1321)	18.8	(248/1322)	15.4	(224/1455)	13.1	(191/1458)	15.3	(219/1435)	16.2	(237/1461)

MS = Male Urethral Swab; **MU** = Male Urine; **FS** = Female Endocervical Swab; **FU** = Female Urine;
PVS = Patient-Collected Vaginal Swab; **CVS** = Clinician-Collected Vaginal Swab.

Table 1b: Positivity of *C. trachomatis* by Clinical Site and Overall as Determined by Aptima CT Assay Results on the DTS System Using PreservCyt Solution Pap Specimens

Site	% (#positive / #tested)	
1	17.0	(17/100)
2	3.2	(4/124)
3	7.4	(35/475)
4	4.2	(12/287)
5	5.4	(16/297)
6	5.5	(20/364)
All	6.3	(104/1647)

Table 1c: Positivity of *C. trachomatis* as Determined by the Aptima CT Assay Results on the Panther System in Patient-collected Vaginal Swab, Female Urine, and Male Urine Samples by Clinical Site

Site	% (# positive / # tested)		
	PVS	FU	MU
1	36.4 (8/22)	45.5 (10/22)	11.9 (21/177)
2	3.1 (12/385)	2.6 (10/385)	0.8 (3/373)
3	6.5 (5/77)	3.9 (3/77)	3.3 (2/61)

4	20.0 (1/5)	0 (0/5)	0 (0/13)
5	11.2 (29/258)	8.3 (21/253)	7.6 (31/409)
6	10.7 (53/494)	9.5 (46/484)	16.3 (50/307)
7	16.8 (42/250)	16.7 (41/246)	10.2 (23/226)
8	5.5 (6/110)	3.6 (4/111)	6.3 (2/32)
9	2.5 (8/314)	2.3 (6/260)	0.9 (2/221)
10	7.5 (19/253)	6.8 (17/251)	13.2 (12/91)
11	3.1 (3/97)	2.2 (2/92)	0 (0/54)
All	8.2 (186/2265)	7.3 (160/2186)	7.4 (146/1964)

FU = female urine; MU = male urine; PVS = patient-collected vaginal swab.

Positive and Negative Predictive Values for Hypothetical Prevalence Rates in North America

The estimated positive and negative predictive values (PPV and NPV) for different hypothetical prevalence rates using the Aptima CT assay on the DTS system are shown in Table 2a. These calculations are based on hypothetical prevalence rates and the overall sensitivity and specificity estimated from the patient infected status for three multi-center clinical investigations. The overall sensitivity and specificity for the Aptima CT assay on the DTS system were 96.7% and 96.8%, respectively (Table 2a). The actual PPV and NPV for clinician-collected endocervical, vaginal and male urethral swab, patient-collected vaginal swab, and male and female urine specimens using the Aptima CT assay on the DTS system are shown in Table 6a for each clinical site and overall. The actual PPV and NPV for PreservCyt solution Pap specimens using the Aptima CT assay on the DTS system are shown in Table 6b.

Table 2a: Positive and Negative Predictive Values for Hypothetical Prevalence Rates on the DTS System

Hypothetical Prevalence Rate (%)	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
1	96.7	96.8	23.5	100.0
2	96.7	96.8	38.3	99.9
5	96.7	96.8	61.6	99.8
10	96.7	96.8	77.2	99.6
15	96.7	96.8	84.3	99.4
20	96.7	96.8	88.4	99.2
25	96.7	96.8	91.0	98.9
30	96.7	96.8	92.9	98.6

The estimated PPV and NPV of the Aptima CT assay on the Panther system across different hypothetical prevalence rates are shown for each specimen type in Table 2b. For each specimen type, the PPV and NPV are derived for different hypothetical prevalence rates using the overall sensitivity and specificity estimates from the multi-center clinical study (see Table 8).

Table 2b: Positive and Negative Predictive Values for Hypothetical Prevalence Rates by Specimen Type on the Panther System

Specimen Type		Hypothetical Prevalence						
		1%	2%	5%	10%	15%	20%	25%
PVS	PPV (%)	66.7	80.2	91.2	95.6	97.2	98.0	98.5
	NPV (%)	100	99.9	99.7	99.5	99.1	98.8	98.4
FU	PPV (%)	69.1	81.9	92.1	96.1	97.5	98.2	98.7
	NPV (%)	100	100	99.9	99.8	99.7	99.5	99.4
MU	PPV (%)	78.4	88.0	95.0	97.6	98.4	98.9	99.2
	NPV (%)	100	100	99.9	99.8	99.8	99.7	99.5

FU = female urine; MU = male urine; NPV = negative predictive value; PPV = positive predictive value; PVS = patient-collected vaginal swab.

Aptima CT Assay on the DTS System RLU Distribution

Figure 2 shows the RLU distribution for the Aptima CT assay for all clinician-collected endocervical, vaginal, and male urethral swab specimens, patient-collected vaginal swab specimens, and male and female urine specimens. Table 3 summarizes the RLU distribution for the total positive and total negative results, as well as the false positive and false negative results for each specimen type. Across certain specimen types, there is a trend toward an increasing proportion of true positives as the RLU values increase.




Figure 2. Frequency of RLU Distribution for the Aptima CT Assay on the DTS System

Table 3: Aptima CT Assay RLU Distribution on the DTS System

	RLUs (x 1000)												
	0 < 10	10 < 20	20 < 30	30 < 40	40 < 50	50 < 100	100 < 1000	1000 < 2000	2000 < 3000	3000 < 4000	4000 < 5000	5000 < 6000	> 6000
Total Positives						0	50	22	14	16	18	92	1035
Total False Positives						0	43	17	7	11	10	25	126
CVS						0	18	4	1	4	4	6	28
PVS						0	7	5	2	1	2	2	6
FS						0	9	2	3	2	2	5	26
MS						0	3	4	0	1	0	3	32
FU						0	5	2	0	1	0	6	12
MU						0	1	0	1	2	2	3	22
Total Negatives	6293	48	10	8	6	0							
Total False Negatives	31	1	0	1	0	0							
CVS	4	0	0	1	0	0							
PVS	1	0	0	0	0	0							
FS	3	0	0	0	0	0							
MS	4	1	0	0	0	0							
FU	10	0	0	0	0	0							
MU	9	0	0	0	0	0							

CVS = clinician-collected vaginal swab; **PVS** = asymptomatic patient-collected vaginal swab; **FS** = female endocervical swab; **MS** = male urethral swab; **FU** = female urine; **MU** = male urine, **RLU** = relative light unit.

Shaded column denotes equivocal zone.

DTS System Clinical Performance

Clinical Specimen Study — Endocervical Swab, Male Urethral Swab, Vaginal Swab, and Urine Specimens

Clinician-collected endocervical, vaginal and male urethral swab, patient-collected vaginal swab, and male and female urine specimens were collected from 2,787 symptomatic and asymptomatic, male and female subjects attending OB/GYN, sexually transmitted disease (STD), teen, and family planning clinics at eight geographically diverse clinical sites in North America. Subjects were classified as symptomatic if symptoms such as discharge, dysuria, and pelvic pain were reported by the subject. Subjects were classified as asymptomatic if the subject did not report symptoms. Of the 1,392 asymptomatic subjects enrolled in the study, 2 were less than 16 years of age, 237 were between the ages of 16 and 20, 423 were between the ages of 21 and 25, and 730 were greater than 25 years of age. Of the 1,395 symptomatic subjects enrolled in the study, 211 were between the ages of 16 and 20, 494 were between the ages of 21 and 25, and 690 were greater than 25 years of age.

Three specimens were collected from each of the 1,322 eligible male subjects. Five specimens were collected from each of the 1,465 eligible female subjects. For male subjects, two randomized urethral swabs were collected followed by one urine specimen. For female subjects, one urine specimen was collected followed by one patient-collected vaginal swab, one clinician-collected vaginal swab, and two randomized endocervical swabs. Aptima CT assay and Aptima Combo 2® Assay CT results were generated from the two vaginal swabs, one endocervical swab, one male urethral swab, and a male and female urine aliquot. The remaining endocervical swab, male urethral swab, and a male and female urine aliquot were tested using another commercially-available NAAT. Endocervical and male urethral swab specimens and male and female urine specimens tested in the Aptima Combo 2 assay and the other commercially available NAAT were used as the reference NAATs to determine infected status for each subject. Specimen testing was conducted either at the site of subject enrollment or at an external testing site.

All performance calculations were based on the total number of Aptima CT assay results for endocervical, vaginal and male urethral swab, and male and female urine specimens compared to a patient infected status algorithm for each gender. In the algorithm, the designation of a subject as being infected or not infected with CT was based on endocervical swab and urine specimen results from the commercially-available Aptima Combo 2 assay and the other commercially-available NAAT. Subjects were considered infected with CT if two of the four endocervical swab and urine specimens tested positive in the Aptima Combo 2 assay and the other reference NAAT (one specimen testing positive in each NAAT). Subjects were considered non-infected if less than two reference NAAT results were positive.

A total of 8,406 Aptima CT assay results were used to calculate sensitivity and specificity. Sensitivity and specificity for CT by gender, specimen type and symptom status are presented in Table 4. Table 6a shows the Aptima CT assay sensitivity, specificity, and predictive values compared to patient infected status for each clinical site and overall. Tables 6b–6f summarize the number of results from symptomatic and asymptomatic subjects designated as infected or non-infected with CT according to the patient infected status algorithm.

Of the 2,787 subjects enrolled, there were 13 subjects with unknown CT patient infected status. Subjects were designated with an unknown patient infected status if results were missing that prevented conclusive determination of infected status. These subjects' results were not included in any performance calculations. Of the 8,452 Aptima CT assay results from the multi-center clinical study, there was a small percentage (8, 0.09%) of specimens

that initially tested invalid for CT. Upon repeat testing, there were no equivocal or invalid results

Table 4: Sensitivity and Specificity of the Aptima CT Assay Relative to Patient Infected Status by Symptom Status and Overall

Specimen	Symptom Status	N	TP	FP	TN	FN	Sensitivity (95% CI)		Specificity (95% CI)		
Male	Swab	Symptomatic	576	131	23 ^a	418	4	97.0	(92.6–99.2)	94.8	(92.3–96.7)
		Asymptomatic	745	90	20 ^b	634	1	98.9	(94.0–100)	96.9	(95.3–98.1)
		All	1321	221	43 ^c	1052	5	97.8	(94.9–99.3)	96.1	(94.7–97.1)
	Urine	Symptomatic	576	127	14 ^d	427	8	94.1	(88.7–97.4)	96.8	(94.7–98.3)
		Asymptomatic	746	90	17 ^e	638	1	98.9	(94.0–100)	97.4	(95.9–98.5)
		All	1322	217	31 ^f	1065	9	96.0	(92.6–98.2)	97.2	(96.0–98.1)
Female	Swab	Symptomatic	807	114	28 ^g	664	1	99.1	(95.3–100)	96.0	(94.2–97.3)
		Asymptomatic	636	59	22 ^h	553	2	96.7	(88.7–99.6)	96.2	(94.3–97.6)
		All	1443	173	50 ⁱ	1217	3	98.3	(95.1–99.6)	96.1	(94.8–97.1)
	Urine	Symptomatic	809	107	13 ^j	682	7	93.9	(87.8–97.5)	98.1	(96.8–99.0)
		Asymptomatic	639	58	13 ^k	565	3	95.1	(86.3–99.0)	97.8	(96.2–98.8)
		All	1448	165	26 ^l	1247	10	94.3	(89.7–97.2)	98.0	(97.0–98.7)
Patient-Collected	Vaginal Swab	Asymptomatic	629	60	25 ^m	543	1	98.4	(91.2–100)	95.6	(93.6–97.1)
Clinician-Collected	Vaginal Swab	Symptomatic	811	111	33 ⁿ	663	4	96.5	(91.3–99.0)	95.3	(93.4–96.7)
		Asymptomatic	638	60	32 ^o	545	1	98.4	(91.2–99.0)	94.5	(92.3–96.2)
		All	1449	171	65 ^p	1208	5	97.2	(93.5–99.1)	94.9	(93.5–96.0)

TP = true positive; FP = false positive; TN = true negative; FN = false negative; CI = confidence interval.

Aptima Combo 2 Assay CT results: # positive results / # specimens tested ^a9/23; ^b14/20; ^c23/43; ^d6/14; ^e6/17; ^f12/31; ^g14/28; ^h11/22; ⁱ25/50; ^j7/13; ^k5/13; ^l12/26; ^m15/25; ⁿ17/33; ^o15/32; ^p32/65.

Clinical Specimen Study — PreservCyt Solution Pap

A prospective multi-center clinical study was conducted to evaluate the use of the PreservCyt solution (a component of the ThinPrep system) as an alternative medium for gynecological specimens for the detection of CT by the Aptima CT assay. One thousand six hundred forty-seven (1,647) symptomatic and asymptomatic female subjects attending OB/GYN, family planning, public health, women's, and STD clinics were evaluated in the clinical study. Of the 1,647 evaluable subjects, 1,288 were asymptomatic subjects and 359 were symptomatic subjects. Subjects were enrolled from sites with CT prevalence that ranged from 2.8% to 14.0%.

Two specimens were collected from each eligible subject: one PreservCyt solution Pap specimen and one endocervical swab specimen. PreservCyt solution Pap specimens were collected with the spatula/cyto-brush or a broom-like brush cervical sampling device. The distribution of cervical sampling devices is summarized in Table 5a by specimen collection site and overall.

PreservCyt solution Pap specimens were processed in accordance with the *ThinPrep Processor Operator's Manual* and Aptima Specimen Transfer Kit package insert. After processing the PreservCyt solution Pap specimen with the ThinPrep processor, the specimen was transferred into the Aptima specimen transfer kit for testing with the Aptima CT assay.

Sensitivity and specificity of the Aptima CT assay in PreservCyt solution Pap specimens were calculated by comparing results to a patient infected status algorithm. The algorithm included Aptima Combo 2 assay and Aptima CT assay results in endocervical swab specimens. Both reference NAATs were required to be positive to establish an infected patient status. At least one reference NAAT was required to be negative to establish a non-infected patient status. Table 6g summarizes the frequency of test outcomes for the two reference NAATs.

Table 5b shows the sensitivities and specificities of the Aptima CT assay by symptom status and overall. Overall sensitivity was 95.6% (86/90). In symptomatic and asymptomatic subjects, sensitivities were 96.7% (29/30) and 95.0% (57/60), respectively. Overall specificity was 98.8% (1539/1557). In symptomatic and asymptomatic subjects, specificities were 98.8% (325/329) and 98.9% (1214/1228), respectively.

Table 6b shows the sensitivities and specificities of the Aptima CT assay by specimen collection site and overall. Sensitivities ranged from 92.9% to 100%. Specificities ranged from 96.5% to 100%.

Table 5a: Distribution of Cervical Sampling Device Used for PreservCyt Solution Pap Specimens

Cervical Sampling Device Used	Clinical Collection Site						Total
	1	2	3	4	5	6	
Spatula/Cytobrush	0	124	475	287	57	364	1307
Broom-Type Device	100	0	0	0	240	0	340

Table 5b: Sensitivity and Specificity of the Aptima CT Assay Relative to Patient Infected Status by Symptom Status and Overall for PreservCyt Solution Pap Specimens

Specimen	Aptima CT PreservCyt Solution Result	+/+	+/-	-/+	-/-	Sensitivity (%) (95% CI)	Specificity (%) (95% CI)
Symptomatic	Positive	29	0	1	3	96.7 (29/30) (82.8–99.9)	98.8 (325/329) (96.9–99.7)
	Negative	1	3	3	319		
	Total	30	3	4	322		
Asymptomatic	Positive	57	0	1	13	95.0 (57/60) (86.1–99.0)	98.9 (1214/1228) (98.1–99.4)
	Negative	3	2	11	1201		
	Total	60	2	12	1214		
All	Positive	86	0	2	16	95.6 (86/90) (89.0–98.8)	98.8 (1539/1557) (98.2–99.3)
	Negative	4	5	14	1520		
	Total	90	5	16	1536		

CI = confidence interval.

+/+ = Positive endocervical swab specimen result in the Aptima Combo 2 Assay/Positive endocervical swab specimen result in the Aptima CT Assay.

+/- = Positive endocervical swab specimen result in the Aptima Combo 2 Assay/Negative endocervical swab specimen result in the Aptima CT Assay.

-/+ = Negative endocervical swab specimen result in the Aptima Combo 2 Assay/Positive endocervical swab specimen result in the Aptima CT Assay.

-/- = Negative endocervical swab specimen result in the Aptima Combo 2 Assay/Negative endocervical swab specimen result in the Aptima CT Assay.

Table 6a: Sensitivity, Specificity and Predictive Values of the Aptima CT Assay Relative to Patient Infected Status by Clinical Site and Overall

Specimen	Site	N	TP	FP	TN	FN	Prev. (%)	Sensitivity (95% CI)	Specificity (95% CI)	PPV (%)	NPV (%)
Swab	1	252	54	14	183	1	21.8	98.2 (90.3–100)	92.9 (88.4–96.1)	79.4	99.5
	2	354	83	15	252	4	24.6	95.4 (88.6–98.7)	94.4 (90.9–96.8)	84.7	98.4
	3	4	1	0	3	0	25.0	100 (2.5–100)	100 (29.2–100)	100	100
	4	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	5	200	12	4	184	0	6.0	100 (73.5–100)	97.9 (94.6–99.4)	75.0	100
	6	304	59	10	235	0	19.4	100 (93.9–100)	95.9 (92.6–98.0)	85.5	100
	7	207	12	0	195	0	5.8	100 (73.5–100)	100 (98.1–100)	100	100
	8	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	All	1321	221	43	1052	5	17.1	97.8 (94.9–99.3)	96.1 (94.7–97.1)	83.7	99.4
Male	1	252	54	9	188	1	21.8	98.2 (90.3–100)	95.4 (91.5–97.9)	85.7	99.5
	2	354	85	9	258	2	24.6	97.7 (91.9–99.7)	96.6 (93.7–98.4)	90.4	99.2
	3	4	1	0	3	0	25.0	100 (2.5–100)	100 (29.2–100)	100	100
	4	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	5	200	12	4	184	0	6.0	100 (73.5–100)	97.9 (94.6–99.4)	75.0	100
	6	305	53	8	238	6	19.3	89.8 (79.2–96.2)	96.7 (93.7–98.6)	86.9	97.5
	7	207	12	1	194	0	5.8	100 (73.5–100)	99.5 (97.2–100)	92.3	100
	8	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	All	1322	217	31	1065	9	17.1	96.0 (92.6–98.2)	97.2 (96.0–98.1)	87.5	99.2
Urine	1	252	54	9	188	1	21.8	98.2 (90.3–100)	95.4 (91.5–97.9)	85.7	99.5
	2	354	85	9	258	2	24.6	97.7 (91.9–99.7)	96.6 (93.7–98.4)	90.4	99.2
	3	4	1	0	3	0	25.0	100 (2.5–100)	100 (29.2–100)	100	100
	4	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	5	200	12	4	184	0	6.0	100 (73.5–100)	97.9 (94.6–99.4)	75.0	100
	6	305	53	8	238	6	19.3	89.8 (79.2–96.2)	96.7 (93.7–98.6)	86.9	97.5
	7	207	12	1	194	0	5.8	100 (73.5–100)	99.5 (97.2–100)	92.3	100
	8	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	All	1322	217	31	1065	9	17.1	96.0 (92.6–98.2)	97.2 (96.0–98.1)	87.5	99.2

Table 6a: Sensitivity, Specificity and Predictive Values of the Aptima CT Assay Relative to Patient Infected Status by Clinical Site and Overall (continued)

Specimen	Site	N	TP	FP	TN	FN	Prev. (%)	Sensitivity (95% CI)		Specificity (95% CI)		PPV (%)	NPV (%)	
Female	Swab	1	228	36	2	190	0	15.8	100	(90.3–100)	99.0	(96.3–99.9)	94.7	100
		2	198	52	18	128	0	26.3	100	(93.2–100)	87.7	(81.2–92.5)	74.3	100
		3	114	9	4	101	0	7.9	100	(66.4–100)	96.2	(90.5–99.0)	69.2	100
		4	260	19	11	229	1	7.7	95.0	(75.1–99.9)	95.4	(91.9–97.7)	63.3	99.6
		5	199	13	5	181	0	6.5	100	(75.3–100)	97.3	(93.8–99.1)	72.2	100
		6	294	33	9	252	0	11.2	100	(89.4–100)	96.6	(93.6–98.4)	78.6	100
		7	102	8	0	92	2	9.8	80.0	(44.4–97.5)	100	(96.1–100)	100	97.9
		8	48	3	1	44	0	6.3	100	(29.2–100)	97.8	(88.2–99.9)	75.0	100
		All	1443	173	50	1217	3	12.2	98.3	(95.1–99.6)	96.1	(94.8–97.1)	77.6	99.8
	Urine	1	227	34	5	187	1	15.4	97.1	(85.1–99.9)	97.4	(94.0–99.1)	87.2	99.5
		2	198	51	2	144	1	26.3	98.1	(89.7–100)	98.6	(95.1–99.8)	96.2	99.3
		3	113	9	1	103	0	8.0	100	(66.4–100)	99.0	(94.8–100)	90.0	100
		4	265	18	4	241	2	7.5	90.0	(68.3–98.8)	98.4	(95.9–99.6)	81.8	99.2
		5	199	11	4	182	2	6.5	84.6	(54.6–98.1)	97.8	(94.6–99.4)	73.3	98.9
		6	295	29	10	252	4	11.2	87.9	(71.8–96.6)	96.2	(93.1–98.2)	74.4	98.4
		7	102	10	0	92	0	9.8	100	(69.2–100)	100	(96.1–100)	100	100
		8	49	3	0	46	0	6.1	100	(29.2–100)	100	(92.3–100)	100	100
		All	1448	165	26	1247	10	12.1	94.3	(89.7–97.2)	98.0	(97.0–98.7)	86.4	99.2
Patient- Collected	Vaginal Swab	1	70	14	4	52	0	20.0	100	(76.8–100)	92.9	(82.7–98.0)	77.8	100
		2	46	13	4	29	0	28.3	100	(75.3–100)	87.9	(71.8–96.6)	76.5	100
		3	45	4	2	39	0	8.9	100	(39.8–100)	95.1	(83.5–99.4)	66.7	100
		4	152	6	3	142	1	4.6	85.7	(42.1–99.6)	97.9	(94.1–99.6)	66.7	99.3
		5	130	7	3	120	0	5.4	100	(59.0–100)	97.6	(93.0–99.5)	70.0	100
		6	75	8	5	62	0	10.7	100	(63.1–100)	92.5	(83.4–97.5)	61.5	100
		7	68	5	2	61	0	7.4	100	(47.8–100)	96.8	(89.0–99.6)	71.4	100
		8	43	3	2	38	0	7.0	100	(29.2–100)	95.0	(83.1–99.4)	60.0	100
		All	629	60	25	543	1	9.7	98.4	(91.2–100)	95.6	(93.6–97.1)	70.6	99.8
Clinician- Collected	Vaginal Swab	1	228	36	8	184	0	15.8	100	(90.3–100)	95.8	(92.0–98.2)	81.8	100
		2	198	50	16	130	2	26.3	96.2	(86.8–99.5)	89.0	(82.8–93.6)	75.8	98.5
		3	113	9	4	100	0	8.0	100	(66.4–100)	96.2	(90.4–98.9)	69.2	100
		4	263	18	14	229	2	7.6	90.0	(68.3–98.8)	94.2	(90.5–96.8)	56.3	99.1
		5	199	13	7	179	0	6.5	100	(75.3–100)	96.2	(92.4–98.5)	65.0	100
		6	296	33	15	248	0	11.1	100	(89.4–100)	94.3	(90.8–96.8)	68.8	100
		7	102	9	0	92	1	9.8	90.0	(55.5–99.7)	100	(96.1–100)	100	98.9
		8	50	3	1	46	0	6.0	100	(29.2–100)	97.9	(88.7–99.9)	75.0	100
		All	1449	171	65	1208	5	12.1	97.2	(93.5–99.1)	94.9	(93.5–96.0)	72.5	99.6

TP = true positive; FP = false positive; TN = true negative; FN = false negative; Prev = prevalence; PPV = positive predictive value; NPV = negative predictive value; N/A = Specimen not obtained or available for testing.

Table 6b: Sensitivity, Specificity and Predictive Values of the Aptima CT Assay Relative to Patient Infected Status by Clinical Site and Overall for PreservCyt Solution Pap Specimens

Site	Aptima CT PreservCyt Solution Result	+/+	+/-	-/+	-/-	Prev (%)	Sensitivity (%) (95% CI)	Specificity (%) (95% CI)	PPV (%)	NPV (%)
1	Positive	14	0	1	2	14.0	100 (14/14) (76.8–100)	96.5 (83/86) (90.1–99.3)	82.4	100
	Negative	0	0	0	83					
	Total	14	0	1	85					
2	Positive	4	0	0	0	3.2	100 (4/4) (39.8–100)	100 (120/120) (97.0–100)	100	100
	Negative	0	0	2	118					
	Total	4	0	2	118					
3	Positive	29	0	0	6	6.5	93.5 (29/31) (78.6–99.2)	98.6 (438/444) (97.1–99.5)	82.9	99.5
	Negative	2	0	2	436					
	Total	31	0	2	442					
4	Positive	8	0	0	4	2.8	100 (8/8) (63.1–100)	98.6 (275/279) (96.4–99.6)	66.7	100
	Negative	0	3	1	271					
	Total	8	3	1	275					
5	Positive	13	0	0	3	4.7	92.9 (13/14) (66.1–99.8)	98.9 (280/283) (96.9–99.8)	81.3	99.6
	Negative	1	1	4	275					
	Total	14	1	4	278					
6	Positive	18	0	1	1	5.2	94.7 (18/19) (74.0–99.9)	99.4 (343/345) (97.9–99.9)	90.0	99.7
	Negative	1	1	5	337					
	Total	19	1	6	338					
All	Positive	86	0	2	16	5.5	95.6 (86/90) (89.0–98.8)	98.8 (1539/1557) (98.2–99.3)	82.7	99.7
	Negative	4	5	14	1520					
	Total	90	5	16	1536					

CI = confidence interval; Prev = prevalence; PPV = positive predictive value; NPV = negative predictive value.

+/+ = Positive endocervical swab specimen result in the Aptima Combo 2 Assay/Positive endocervical swab specimen result in the Aptima CT Assay.

+/- = Positive endocervical swab specimen result in the Aptima Combo 2 Assay/Negative endocervical swab specimen result in the Aptima CT Assay.

-/+ = Negative endocervical swab specimen result in the Aptima Combo 2 Assay/Positive endocervical swab specimen result in the Aptima CT Assay.

-/- = Negative endocervical swab specimen result in the Aptima Combo 2 Assay/Negative endocervical swab specimen result in the Aptima CT Assay.

Table 6c: Male Urethral Swab and Urine Results from Subjects Infected or Non-Infected with *C. trachomatis* According to Patient Infected Status

Patient Infected Status	NAAT 1 (Aptima Combo 2 Assay)		NAAT 2		Aptima CT Assay		Symptom Status		Total
	MS	MU	MS	MU	MS	MU	Symptomatic	Asymptomatic	
Infected	+	+	+	+	+	+	96	68	164
Infected	+	+	+	+	+	-	5	1	6
Infected	+	+	+	-	+	+	11	7	18
Infected	+	+	-	+	+	+	13	11	24
Infected	+	+	-	+	+	-	1	0	1
Infected	+	+	-	+	-	+	1	0	1
Infected	+	-	+	+	+	+	2	0	2
Infected	+	-	+	+	+	-	1	0	1
Infected	+	-	+	-	+	-	1	0	1
Infected	-	+	+	+	+	+	1	0	1
Infected	-	+	-	+	+	+	0	2	2
Infected	-	+	-	+	-	+	3	1	4
Infected	-	+	=	+	+	+	0	1	1
Non-infected	+	+	-	-	+	+	4	4	8
Non-infected	+	+	-	-	-	+	1	0	1
Non-infected	+	-	-	-	+	+	1	4	5
Non-infected	+	-	-	-	+	-	4	6	10
Non-infected	+	-	-	-	-	+	1	0	1
Non-infected	+	-	-	-	-	-	3	0	3
Non-infected	-	+	-	-	+	+	1	0	1
Non-infected	-	+	-	-	-	+	0	2	2
Non-infected	-	+	-	-	-	-	1	0	1
Non-infected	-	-	+	+	+	+	1	0	1
Non-infected	-	-	-	+	-	-	2	2	4
Non-infected	-	-	-	-	+	+	1	1	2
Non-infected	-	-	-	-	+	-	11	5	16
Non-infected	-	-	-	-	-	+	4	4	8
Non-infected	-	-	-	-	-	-	403	618	1021
Non-infected	-	-	-	N/A	-	+	0	2	2
Non-infected	-	-	-	N/A	-	-	1	2	3
Non-infected	-	-	-	=	-	-	0	4	4
Non-infected	-	-	=	-	-	-	2	0	2
Non-infected	N/A	-	-	-	N/A	-	0	1	1
Total							576	746	1322

N/A = Specimen not obtained or available for testing. The equal symbol (=) represents equivocal or indeterminate on repeat testing.
MS = male urethral swab; **MU** = male urine.

Table 6d: Female Endocervical Swab and Urine Results from Subjects Infected or Non-Infected with *C. trachomatis* According to Patient Infected Status

Patient Infected Status	NAAT 1 (Aptima Combo 2 Assay)		NAAT 2		Aptima CT Assay		Symptom Status		Total
	FS	FU	FS	FU	FS	FU	Symptomatic	Asymptomatic	
Infected	+	+	+	+	+	+	80	43	123
Infected	+	+	+	+	+	-	1	1	2
Infected	+	+	+	-	+	+	10	5	15
Infected	+	+	+	=	+	+	1	0	1
Infected	+	+	-	+	+	+	9	3	12
Infected	+	-	+	+	+	+	3	1	4
Infected	+	-	+	+	+	-	2	2	4
Infected	+	-	+	-	+	+	2	0	2
Infected	+	-	+	-	+	-	4	0	4
Infected	+	-	+	-	+	N/A	1	0	1
Infected	-	+	+	+	+	+	0	1	1
Infected	-	+	-	+	+	+	1	3	4
Infected	-	+	-	+	-	+	1	2	3
Non-infected	+	+	-	-	+	+	1	2	3
Non-infected	+	+	-	N/A	+	+	1	0	1
Non-infected	+	-	-	-	+	+	0	2	2
Non-infected	+	-	-	-	+	-	12	7	19
Non-infected	+	-	-	-	-	-	0	1	1
Non-infected	-	+	-	-	+	+	1	0	1
Non-infected	-	+	-	-	-	+	4	3	7
Non-infected	-	+	-	-	-	-	0	1	1
Non-infected	-	-	+	-	-	-	1	1	2
Non-infected	-	-	-	+	-	-	1	2	3
Non-infected	-	-	-	-	+	+	0	2	2
Non-infected	-	-	-	-	+	-	11	9	20
Non-infected	-	-	-	-	-	+	5	4	9
Non-infected	-	-	-	-	-	-	636	526	1162
Non-infected	-	-	-	-	-	N/A	1	0	1
Non-infected	-	-	-	N/A	-	-	2	3	5
Non-infected	-	-	-	=	-	-	12	10	22
Non-infected	-	-	=	-	-	-	1	1	2
Non-infected	-	N/A	-	-	-	N/A	1	1	2
Non-infected	N/A	-	-	-	N/A	-	5	4	9
Non-infected	=	-	-	-	+	+	1	0	1
Non-infected	=	-	-	-	+	-	1	0	1
Total							812	640	1452

N/A = Specimen not obtained or available for testing. The equal symbol (=) represents equivocal or indeterminate on repeat testing.

FS = female endocervical swab; FU = female urine.

Table 6e: Asymptomatic Patient-Collected Vaginal Swab Results from Subjects Infected or Non-Infected with *C. trachomatis* According to Patient Infected Status

Patient Infected Status	NAAT 1 (Aptima Combo 2 Assay)		NAAT 2		Aptima CT Assay	Total
	FS	FU	FS	FU	PVS	
Infected	+	+	+	+	+	44
Infected	+	+	+	-	+	5
Infected	+	+	-	+	+	3
Infected	+	-	+	+	+	3
Infected	-	+	+	+	+	1
Infected	-	+	-	+	+	4
Infected	-	+	-	+	-	1
Non-infected	+	+	-	-	+	2
Non-infected	+	-	-	-	+	4
Non-infected	+	-	-	-	+	1
Non-infected	+	-	-	-	-	2
Non-infected	+	-	-	-	-	3
Non-infected	-	+	-	-	+	2
Non-infected	-	+	-	-	-	2
Non-infected	-	-	+	-	-	1
Non-infected	-	-	-	+	-	2
Non-infected	-	-	-	-	+	5
Non-infected	-	-	-	-	+	10
Non-infected	-	-	-	-	-	15
Non-infected	-	-	-	-	-	500
Non-infected	-	-	-	-	-	1
Non-infected	-	-	-	-	N/A	1
Non-infected	-	-	-	-	N/A	9
Non-infected	-	-	-	N/A	-	2
Non-infected	-	-	-	N/A	N/A	1
Non-infected	-	-	-	=	-	1
Non-infected	-	-	-	=	-	8
Non-infected	-	-	-	=	-	1
Non-infected	-	-	=	-	-	1
Non-infected	-	N/A	-	-	-	1
Non-infected	N/A	-	-	-	+	1
Non-infected	N/A	-	-	-	-	3
Total						640

N/A = Specimen not obtained or available for testing. The equal symbol (=) represents equivocal or indeterminate on repeat testing.

FS = female endocervical swab; **FU** = female urine; **PVS** = asymptomatic patient-collected vaginal swab.

Table 6f: Clinician-Collected Vaginal Swab Results from Subjects Infected or Non-Infected with *C. trachomatis* According to Patient Infected Status

Patient Infected Status	NAAT 1 (Aptima Combo 2 Assay)		NAAT 2		Aptima CT Assay	Symptom Status		Total
	FS	FU	FS	FU	CVS	Symptomatic	Asymptomatic	
Infected	+	+	+	+	+	76	44	120
Infected	+	+	+	+	-	2	0	2
Infected	+	+	+	+	+	2	0	2
Infected	+	+	+	+	+	1	0	1
Infected	+	+	+	-	+	8	5	13
Infected	+	+	+	-	-	1	0	1
Infected	+	+	+	-	+	1	0	1
Infected	+	+	+	=	+	1	0	1
Infected	+	+	-	+	+	9	3	12
Infected	+	-	+	+	+	5	3	8
Infected	+	-	+	-	+	7	0	7
Infected	-	+	+	+	+	0	1	1
Infected	-	+	-	+	+	1	4	5
Infected	-	+	-	+	-	1	0	1
Infected	-	+	-	+	-	0	1	1
Non-infected	+	+	-	-	+	1	2	3
Non-infected	+	+	-	N/A	+	1	0	1
Non-infected	+	-	-	-	+	3	4	7
Non-infected	+	-	-	-	-	0	1	1
Non-infected	+	-	-	-	+	2	2	4
Non-infected	+	-	-	-	-	5	3	8
Non-infected	+	-	-	-	+	1	0	1
Non-infected	+	-	-	-	-	1	0	1
Non-infected	-	+	-	-	+	5	2	7
Non-infected	-	+	-	-	-	0	2	2
Non-infected	-	-	+	-	-	1	1	2
Non-infected	-	-	-	+	-	1	2	3
Non-infected	-	-	-	-	+	4	5	9
Non-infected	-	-	-	-	-	6	10	16
Non-infected	-	-	-	-	+	16	15	31
Non-infected	-	-	-	-	-	614	500	1114
Non-infected	-	-	-	-	N/A	0	1	1
Non-infected	-	-	-	-	+	0	1	1
Non-infected	-	-	-	-	-	13	9	22
Non-infected	-	-	-	N/A	-	2	2	4
Non-infected	-	-	-	N/A	-	0	1	1
Non-infected	-	-	-	=	+	0	1	1
Non-infected	-	-	-	=	-	12	8	20
Non-infected	-	-	-	=	N/A	0	1	1
Non-infected	-	-	=	-	-	1	1	2
Non-infected	-	N/A	-	-	-	0	1	1

Table 6f: Clinician-Collected Vaginal Swab Results from Subjects Infected or Non-Infected with *C. trachomatis* According to Patient Infected Status (continued)

Patient Infected Status	NAAT 1 (Aptima Combo 2 Assay)		NAAT 2		Aptima CT Assay	Symptom Status		Total
	FS	FU	FS	FU	CVS	Symptomatic	Asymptomatic	
Non-infected	-	N/A	-	-	N/A	1	0	1
Non-infected	N/A	-	-	-	-	0	1	1
Non-infected	N/A	-	-	-	-	5	3	8
Non-infected	=	-	-	-	-	2	0	2
Total						812	640	1452

N/A = Specimen not obtained or available for testing. The equal symbol (=) represents equivocal or indeterminate on repeat testing.

FS = female endocervical swab; FU = female urine; CVS = clinician-collected vaginal swab.

Table 6g: PreservCyt Solution Clinical Study (Patient Infected Status Results From Endocervical Swab Specimens)

Patient Infected Status	Endocervical Swab		Symptom Status	
	Aptima Combo 2 Assay	Aptima CT Assay	Symptomatic	Asymptomatic
Infected	Positive	Positive	30	60
Non-Infected	Negative	Negative	322	1214
Non-Infected	Negative	Positive	4	12
Non-Infected	Positive	Negative	3	2
Total			359	1288

RLU Distribution of Aptima Controls

The distribution of the RLUs for the Aptima Positive Control, GC / Negative Control, CT and the Aptima Positive Control, CT / Negative Control, GC from all the Aptima CT assay runs performed during the clinical specimen studies are presented in Table 7.

Table 7: Distribution of RLU of the Aptima Controls During the Clinical Specimen Studies Including Endocervical, Vaginal and Male Urethral Swab, Male and Female Urine Specimens, and PreservCyt Solution Pap Studies

Control	Statistics	RLU (x1000)	
		Swab and Urine Specimen Clinical Study	PreservCyt Solution Pap Specimen Clinical Study
Positive Control, GC / Negative Control, CT	N	198	209
	Mean	0.89	1.22
	SD	2.94	2.63
	Maximum	26	36
	75 th Percentile	1	1
	Median	0	1
	25 th Percentile	0	1

Table 7: Distribution of RLU of the Aptima Controls During the Clinical Specimen Studies Including Endocervical, Vaginal and Male Urethral Swab, Male and Female Urine Specimens, and PreservCyt Solution Pap Studies (continued)

Control	Statistics	RLU (x1000)	
		Swab and Urine Specimen Clinical Study	PreservCyt Solution Pap Specimen Clinical Study
Positive Control, CT / Negative Control, GC	N	198	209
	Mean	7007	6593
	SD	776	709
	Maximum	8884	10383
	75 th Percentile	7440	7025
	Median	7066	6661
	25 th Percentile	6621	6205
	Minimum	988	4419

SD = standard deviation; **CV%** = percent coefficient of variation; **RLU** = relative light unit.

Note: The RLU value reported by the software was the bases for analysis. The reported RLU value is the total measured RLU divided by 1000 with the digits after the decimal point truncated.

Panther System Clinical Performance

Clinical Study

A prospective, multicenter clinical study was conducted to establish the clinical performance characteristics of the Aptima CT assay on the Panther system. Specimens were collected from 4413 symptomatic and asymptomatic women and men enrolled at 11 geographically and ethnically diverse US clinical sites, including obstetrics and gynecology, family planning, and STI clinics. Subjects were classified as symptomatic if symptoms were reported by the subject. Subjects were classified as asymptomatic if the subject did not report symptoms. One hundred sixty six (166) enrolled subjects were not evaluable (28 were withdrawn and 138 did not have at least one specimen with a valid non-excluded Aptima CT assay result and a conclusive infected status). Of the 4247 evaluable subjects, 2283 were women and 1964 were men. The average age among evaluable study subjects was 34.5 years (range = 14 to 84 years). Symptoms were reported in 45.7% (1939/4247) of the evaluable subjects.

Up to 5 specimens were collected from each female subject (4 patient-collected vaginal swabs, 1 first-catch urine) and 1 first-catch urine specimen was collected from each male subject. All specimens were collected by the subject at the clinical sites.

Specimens were tested with the Aptima CT assay on the Panther system. Specimens with initial equivocal or invalid Aptima CT assay results or instrument processing errors were retested, volume permitting; valid retest results were included in the performance analyses. Patient-collected vaginal swabs and male and female urine specimens were tested with up to 3 FDA-cleared NAATs to establish the specimen-specific patient infected status (PIS) as follows:

- Male urine PIS was derived from male urine specimens
- Female urine PIS was derived from female urine specimens
- Vaginal swab PIS was derived from vaginal swab and female urine specimens

Performance of the Aptima CT assay was estimated relative to the specimen-specific PIS for each of the specimen types.

Of the specimens collected, 6592 were processed in valid Aptima CT assay runs, including 213 (3.2%) that had to be retested due to invalid results. Overall, 6561 (99.5%) had final valid results, and 31 (0.5%) had final invalid results and were excluded from the analyses. A total of 6415 specimens from 4247 evaluable subjects were included in the analyses comparing Aptima CT assay results to the PIS: 2265 patient-collected vaginal swab, 2186 female urine, and 1964 male urine specimens.

Performance Results

Performance characteristics of the Aptima CT assay were estimated for each specimen type. Table 8 shows the sensitivity, specificity, PPV, and NPV of the Aptima CT assay on the Panther system and the prevalence of *C. trachomatis* (based on the specimen-specific PIS) in each specimen type by symptom status and overall.

Table 8: Performance Characteristics of the Aptima CT Assay by Symptom Status

Specimen Type	Symptom Status	N	TP	FP ¹	TN	FN ²	Prev %	Sensitivity (95% CI) ³	Specificity (95% CI) ³	PPV % (95% CI) ⁴	NPV % (95% CI) ⁴
PVS	All	2265	176	10	2070	9	8.2	95.1 (91.0, 97.4)	99.5 (99.1, 99.7)	94.6 (91.0, 97.6)	99.6 (99.3, 99.8)
	Sym	1102	89	6 ^a	1001	6 ^a	8.6	93.7 (86.9, 97.1)	99.4 (98.7, 99.7)	93.7 (88.4, 98.0)	99.4 (98.9, 99.8)
	Asym	1163	87	4 ^b	1069	3 ^b	7.7	96.7 (90.7, 98.9)	99.6 (99.0, 99.9)	95.6 (91.0, 99.0)	99.7 (99.3, 100)
FU	All	2186	151	9	2023	3	7.0	98.1 (94.4, 99.3)	99.6 (99.2, 99.8)	94.4 (90.7, 97.6)	99.9 (99.7, 100)
	Sym	1050	74	7 ^c	968	1 ^c	7.1	98.7 (92.8, 99.8)	99.3 (98.5, 99.7)	91.4 (84.8, 96.7)	99.9 (99.7, 100)
	Asym	1136	77	2 ^d	1055	2 ^d	7.0	97.5 (91.2, 99.3)	99.8 (99.3, 99.9)	97.5 (93.6, 100)	99.8 (99.5, 100)
MU	All	1964	141	5	1816	2	7.3	98.6 (95.0, 99.6)	99.7 (99.4, 99.9)	96.6 (93.4, 99.3)	99.9 (99.7, 100)
	Sym	828	85	4 ^e	738	1 ^e	10.4	98.8 (93.7, 99.8)	99.5 (98.6, 99.8)	95.5 (90.8, 99.0)	99.9 (99.6, 100)
	Asym	1136	56	1 ^f	1078	1 ^f	5.0	98.2 (90.7, 99.7)	99.9 (99.5, 100)	98.2 (94.0, 100)	99.9 (99.7, 100)

Asym = asymptomatic; **CI** = confidence interval; **FN** = false negative; **FP** = false positive; **FU** = female urine; **MU** = male urine; **Prev** = prevalence; **PVS** = patient-collected vaginal swab; **Sym** = symptomatic; **TN** = true negative; **TP** = true positive; **PPV** = positive predictive value; **NPV** = negative predictive value.

¹Specimens of the same type, unless noted otherwise, were also tested by an alternative *C. trachomatis* NAAT assay with the following results (# positive results / # samples tested): ^a1/6, ^b1/4, ^c2/7, ^d0/2, ^e0/4, ^f0/1.

²Specimens of the same type, unless noted otherwise, were also tested by an alternative *C. trachomatis* NAAT assay with the following results (# negative results / # samples tested): ^a1/6, ^b1/3, ^c1/1, ^d2/2, ^e1/1, ^f0/1.

³Score CI.

⁴Percentile CI obtained using the bootstrap re-sampling method with 2000 iterations.

Table 9 shows the sensitivity, specificity, PPV, and NPV of the Aptima CT assay on the Panther system and the prevalence of *C. trachomatis* (based on the specimen-specific PIS) in each specimen type by collection site. Prevalence varied across collection sites, as expected.

Table 9: Performance Characteristics of the Aptima CT Assay by Collection Site

Specimen Type	Site	N	TP	FP	TN	FN	Prev %	Sensitivity % (95% CI) ¹	Specificity % (95% CI) ¹	PPV % (95% CI) ²	NPV % (95% CI) ²
PVS	1	22	8	0	13	1	40.9	88.9 (56.5, 98.0)	100 (77.2, 100)	100 (NC)	92.9 (78.6, 100)
	2	385	12	0	373	0	3.1	100 (75.8, 100)	100 (99.0, 100)	100 (NC)	100 (NC)
	3	77	5	0	72	0	6.5	100 (56.6, 100)	100 (94.9, 100)	100 (NC)	100 (NC)
	4	5	1	0	4	0	20.0	100 (20.7, 100)	100 (51.0, 100)	100 (NC)	100 (NC)
	5	258	26	3	229	0	10.1	100 (87.1, 100)	98.7 (96.3, 99.6)	89.7 (77.4, 100)	100 (NC)
	6	494	50	3	439	2	10.5	96.2 (87.0, 98.9)	99.3 (98.0, 99.8)	94.3 (87.5, 100)	99.5 (98.8, 100)
	7	250	42	0	206	2	17.6	95.5 (84.9, 98.7)	100 (98.2, 100)	100 (NC)	99.0 (97.5, 100)
	8	110	5	1	104	0	4.5	100 (56.6, 100)	99.0 (94.8, 99.8)	83.3 (50.0, 100)	100 (NC)
	9	314	8	0	304	2	3.2	80.0 (49.0, 94.3)	100 (98.8, 100)	100 (NC)	99.3 (98.4, 100)
	10	253	17	2	232	2	7.5	89.5 (68.6, 97.1)	99.1 (96.9, 99.8)	89.5 (72.5, 100)	99.1 (97.8, 100)
	11	97	2	1	94	0	2.1	100 (34.2, 100)	98.9 (94.3, 99.8)	66.7 (0.0, 100)	100 (NC)

Table 9: Performance Characteristics of the Aptima CT Assay by Collection Site

Specimen Type	Site	N	TP	FP	TN	FN	Prev %	Sensitivity % (95% CI) ¹	Specificity % (95% CI) ¹	PPV % (95% CI) ²	NPV % (95% CI) ²
FU	1	22	9	1	12	0	40.9	100 (70.1, 100)	92.3 (66.7, 98.6)	90.0 (66.7, 100)	100 (NC)
	2	385	9	1	375	0	2.3	100 (70.1, 100)	99.7 (98.5, 100)	90.0 (66.7, 100)	100 (NC)
	3	77	3	0	74	0	3.9	100 (43.9, 100)	100 (95.1, 100)	100 (NC)	100 (NC)
	4	5	0	0	5	0	0.0	NC	100 (56.6, 100)	NC	100 (NC)
	5	253	19	2	231	1	7.9	95.0 (76.4, 99.1)	99.1 (96.9, 99.8)	90.5 (76.5, 100)	99.6 (98.7, 100)
	6	484	44	2	436	2	9.5	95.7 (85.5, 98.8)	99.5 (98.4, 99.9)	95.7 (88.9, 100)	99.5 (98.8, 100)
	7	246	40	1	205	0	16.3	100 (91.2, 100)	99.5 (97.3, 99.9)	97.6 (91.9, 100)	100 (NC)
	8	111	4	0	107	0	3.6	100 (51.0, 100)	100 (96.5, 100)	100 (NC)	100 (NC)
	9	260	6	0	254	0	2.3	100 (61.0, 100)	100 (98.5, 100)	100 (NC)	100 (NC)
	10	251	15	2	234	0	6.0	100 (79.6, 100)	99.2 (97.0, 99.8)	88.2 (70.3, 100)	100 (NC)
	11	92	2	0	90	0	2.2	100 (34.2, 100)	100 (95.9, 100)	100 (NC)	100 (NC)
MU	1	177	20	1	156	0	11.3	100 (83.9, 100)	99.4 (96.5, 99.9)	95.2 (83.3, 100)	100 (NC)
	2	373	3	0	370	0	0.8	100 (43.9, 100)	100 (99.0, 100)	100 (NC)	100 (NC)
	3	61	2	0	59	0	3.3	100 (34.2, 100)	100 (93.9, 100)	100 (NC)	100 (NC)
	4	13	0	0	13	0	0.0	NC	100 (77.2, 100)	NC	100 (NC)
	5	409	30	1	378	0	7.3	100 (88.6, 100)	99.7 (98.5, 100)	96.8 (88.9, 100)	100 (NC)
	6	307	48	2	255	2	16.3	96.0 (86.5, 98.9)	99.2 (97.2, 99.8)	96.0 (89.7, 100)	99.2 (98.0, 100)
	7	226	23	0	203	0	10.2	100 (85.7, 100)	100 (98.1, 100)	100 (NC)	100 (NC)
	8	32	2	0	30	0	6.3	100 (34.2, 100)	100 (88.6, 100)	100 (NC)	100 (NC)
	9	221	1	1	219	0	0.5	100 (20.7, 100)	99.5 (97.5, 99.9)	50.0 (0.0, 100)	100 (NC)
	10	91	12	0	79	0	13.2	100 (75.8, 100)	100 (95.4, 100)	100 (NC)	100 (NC)
	11	54	0	0	54	0	0.0	NC	100 (93.4, 100)	NC	100 (NC)

CI = confidence interval; FN = false negative; FP = false positive; FU = female urine; MU = male urine; NC = not calculable;

Prev = prevalence; PVS = patient-collected vaginal swab; TN = true negative; TP = true positive; PPV = positive predictive value; NPV = negative predictive value.

¹ Score CI.

² Percentile CI obtained using the bootstrap re-sampling method with 2000 iterations. For some collection sites the statistic is not calculable in some bootstrap samples due to a denominator of zero; the percentile CI is computed using the bootstrap samples in which the statistic can be calculated. If in all bootstrap samples the statistic is not calculable, or if the value of the statistic is constant across all bootstrap samples in which the statistic can be calculated, the 95% percentile bootstrap CI is set to NC.

Chlamydia trachomatis Infected Status Tables

The frequency of test outcomes from reference NAAT and investigational Panther system testing is summarized in Table 10a and Table 10b.

Table 10a: *C. trachomatis* Infected Status for Female Urine and Male Urine Specimens

Specimen Type	Patient Infected Status	NAAT 1	NAAT 2	NAAT 3	ACT Assay	Symptom Status	
						Symptomatic	Asymptomatic
FU	Infected	+	+	N/A	+	66	75
	Infected	+	+	N/A	-	1	0
	Infected	+	NR	+	+	2	0
	Infected	-	+	+	+	4	2
	Infected	-	+	+	-	0	1
	Infected	NR	+	+	+	2	0
	Infected	NR	+	+	-	0	1
	Non-infected	+	-	-	-	1	1
	Non-infected	-	+	-	+	3	1
	Non-infected	-	+	-	-	3	1
	Non-infected	-	-	N/A	+	4	1
	Non-infected	-	-	N/A	-	929	1023
	Non-infected	-	NR	-	-	0	1
	Non-infected	NR	-	-	-	35	29
MU	Infected	+	+	N/A	+	83	55
	Infected	+	+	N/A	-	0	1
	Infected	+	-	+	+	1	0
	Infected	-	+	+	+	0	1
	Infected	-	+	+	-	1	0
	Infected	NR	+	+	+	1	0
	Non-infected	-	+	-	+	0	1
	Non-infected	-	+	-	-	3	1
	Non-infected	-	-	N/A	+	4	0
	Non-infected	-	-	N/A	-	702	1046
	Non-infected	-	NR	-	-	2	0
	Non-infected	NR	-	-	-	31	31

ACT Assay = Aptima Chlamydia trachomatis Assay; **FU** = female urine; **MU** = male urine; **N/A** = not applicable; **NR** = no result.

Table 10b: *C. trachomatis* Infected Status for Patient-collected Vaginal Swab Specimens

Patient Infected Status	NAAT 1		NAAT 2		ACT Assay	Symptom Status	
	PVS	FU	PVS	FU		Symptomatic	Asymptomatic
Infected	+	+	+	+	+	60	72
Infected	+	+	+	+	-	2	2
Infected	+	+	+	-	+	3	1
Infected	+	+	+	NR	+	2	0
Infected	+	-	+	+	+	10	5
Infected	+	-	+	+	-	1	0
Infected	+	-	+	-	+	9	6
Infected	+	NR	+	+	+	0	1
Infected	+	NR	+	+	-	1	0
Infected	+	NR	+	-	-	1	0
Infected	-	+	+	+	+	4	1
Infected	-	+	-	+	+	1	0
Infected	-	+	-	+	-	1	1
Infected	NR	+	+	+	+	0	1
Non-infected	+	-	-	-	+	3	0
Non-infected	+	-	-	-	-	2	6
Non-infected	-	-	+	+	-	0	1
Non-infected	-	-	+	-	+	0	1
Non-infected	-	-	+	-	-	1	1
Non-infected	-	-	-	+	-	2	0
Non-infected	-	-	-	-	+	3	3
Non-infected	-	-	-	-	-	904	996
Non-infected	-	-	NR	-	-	13	10
Non-infected	-	-	NR	NR	-	0	1
Non-infected	-	NR	-	-	-	35	25
Non-infected	NR	-	-	-	-	3	5
Non-infected	NR	NR	-	-	-	41	24

ACT Assay = Aptima Chlamydia trachomatis Assay; FU = female urine; NR = no result; PVS = patient-collected vaginal swab.

RLU Distribution of Aptima Chlamydia trachomatis Assay Controls

The distribution of the RLU values for the Aptima CT assay controls is presented in Table 11 from all valid Panther system runs performed during the clinical study.

Table 11: RLU Distribution Aptima CT Assay Negative and Positive Controls

Control	Statistics	Total RLU (x1000)
Positive Control, CT / Negative Control, GC	N	160
	Minimum	3162
	Median	6816.5
	Maximum	8818
	CV%	7.83

Table 11: RLU Distribution Aptima CT Assay Negative and Positive Controls

Control	Statistics	Total RLU (x1000)
Positive Control, GC / Negative Control, CT	N	160
	Minimum	0
	Median	2.0
	Maximum	30
	CV%	137.49

CV% = percent coefficient of variation; RLU = relative light unit.

Note: The RLU value reported by the software was the bases for analysis. The reported RLU value is the total measured RLU divided by 1000 with the digits after the decimal point truncated.

Reproducibility Study

Aptima CT assay reproducibility was evaluated on the Panther system at two external US laboratories and at Hologic. Testing was performed using two lots of assay reagents and a total of six operators (two at each site). At each site, testing was performed over at least six days.

The negative panel member consisted of STM only. The CT positive panel members were created by spiking STM with CT positive cells diluted in STM to achieve the appropriate targeted concentrations (very low positive, low positive, or positive). Final *Chlamydia trachomatis* concentrations ranged from 0.25 IFU/mL to 25 IFU/mL.

The agreement with expected results was 100% for all panel members.

Table 12 shows the signal variability of assay RLU results for each panel member between sites, between operators, between lots, between runs, within runs, and overall (Total). Only samples with valid results were included in the analyses.

Table 12: Reproducibility Study Data: Signal Variability by Panel Member

Panel Member	Target Conc. (IFU/mL)	N	Mean RLU (x1000)	Between Sites		Between Operators		Between Lots		Between Runs		Within Runs		Total	
				SD	CV(%)	SD	CV(%)	SD	CV(%)	SD	CV(%)	SD	CV(%)	SD	CV(%)
Negative	0	107 ¹	1.5	0.8	49.7	0.0	0.0	0.0	0.0	0.1	4.9	1.5	101.1	1.7	112.8
Very Low Positive	0.25	108	7339.0	272.0	3.7	0.0	0.0	80.0	1.1	98.2	1.3	142.0	1.9	331.9	4.5
Low Positive	2.5	108	7387.6	307.8	4.2	0.0	0.0	97.9	1.3	139.9	1.9	114.0	1.5	370.0	5.0
Medium Positive	25	107 ¹	7424.4	285.6	3.8	39.6	0.5	136.9	1.8	91.3	1.2	138.7	1.9	359.8	4.8

CV = coefficient of variation; RLU = relative light unit; SD = standard deviation.

Notes: The RLU value reported by the software is the total measured RLU divided by 1000 with the digits after the decimal point truncated. Variability from some factors may be numerically negative. In these cases, SD and CV are shown as 0.0.

¹ One invalid result was excluded from the analysis.

Clinical Specimen Agreement

The Aptima CT Assay was first launched on semi-automated DTS systems and Tigris DTS system. In 2010, indications were expanded to use the Aptima CT assay on the Panther system. The Panther system is an alternative, smaller instrument platform to the Tigris DTS system. Both systems are intended to fully automated amplified nucleic acid testing of diagnostics assays. Select assay performance testing completed on the semi-automated DTS systems and Tigris DTS system were leveraged to support assay performance on the Panther system.

Sensitivity, specificity, and predictive values of the Aptima CT assay were established using the DTS system. Agreement between Aptima CT assay results generated on the fully automated Tigris DTS system and semi-automated DTS systems was evaluated by testing endocervical swab, male urethral swab, male and female urine, vaginal swab, and PreservCyt solution Pap specimens. Each of the clinical specimens was tested individually with the Aptima CT assay on both the Tigris DTS system and DTS systems at Hologic. The order of testing was not randomized. Specimens identified for inclusion were tested on the Tigris DTS system followed by testing on DTS systems.

Clinical Specimen Agreement Study — Endocervical Swab, Male Urethral Swab, Female and Male Urine, Vaginal Swab, and PreservCyt Solution Pap Specimens

Female and male subjects attending STD, family planning, and OB/GYN clinics from eight geographically diverse sites with low to high prevalence for CT contributed endocervical swab, male urethral swab, female and male urine, vaginal swab, and PreservCyt solution Pap specimens. The specimens were transferred directly to Hologic for testing while the PreservCyt solution Pap specimens were processed at 2 cytopathology laboratories before being transferred. At Hologic, endocervical swab, male urethral swab, female and male urine specimens were first screened with Aptima Combo 2 assay on the Tigris DTS system, and the vaginal swab and PreservCyt solution Pap specimens were screened with Aptima Combo 2 assay on the DTS systems. Specimens with final invalid or equivocal results were not selected in the Aptima CT Clinical Specimen Agreement Study.

Two hundred and five female swabs (87 endocervical and 118 vaginal), 120 male urethral swab, 98 female urine, 115 male urine, and 116 PreservCyt solution Pap specimens with Aptima Combo 2 assay CT positive and negative results were selected for comparison testing between the Tigris DTS system and the DTS systems for the Aptima CT assay. Specimens with initial invalid or equivocal results were retested using the same system on which the result was generated. One female urine specimen had an initial equivocal result on the DTS systems; when retested, the final result was valid. One male urine specimen had an initial invalid result on the Tigris DTS system; when retested, the final result was valid. One female urine specimen had an initial equivocal result on the Tigris DTS system; this specimen was retested, however, the specimen had expired, so the final result was equivocal.

Table 13 shows the positive, negative, and overall agreements for all paired results for each specimen type by symptomatic status. Specimens are relatively imbalanced by symptomatic and asymptomatic status but overall agreements for symptomatic subjects were 98.5% (131/133) for female swabs (combined endocervical and vaginal swabs), 100% (60/60) for male urethral swab, 98.2% (55/56) for female urine specimens, 100% (60/60) for male urine specimens, and 100% (81/81) for PreservCyt solution Pap specimens. For asymptomatic subjects, overall agreements were 100% for 72 female swabs, 60 male urethral swabs, 42 female urine, 55 male urine specimens, and 35 PreservCyt solution Pap specimens,

respectively. For 'All' (symptomatic and asymptomatic combined) subjects, overall agreement was 99.0% (203/205) for female swab (combined endocervical and vaginal swabs), 100% (120/120) for male urethral swab, 99.0% (97/98) for female urine, 100% (115/115) for male urine, and 100% (116/116) for PreservCyt solution Pap specimens. Due to the relatively smaller specimen number from asymptomatic subjects, these findings may not be generalizable to Aptima CT-Tigris system testing with specimens from asymptomatic subjects.

Refer to Tables 3 and 5b for Aptima CT assay sensitivity and specificity estimates from testing on the DTS systems. Sensitivity and specificity of the Aptima CT assay when using the Tigris DTS system would be expected to be similar given the agreement findings.

Table 13: Clinical Specimen Agreement Study: Positive, Negative, and Overall Agreements by Symptom Status

Symptom	Specimen	Gender	n	DTS+ Tigris+	DTS+ Tigris-	DTS- Tigris+	DTS- Tigris-	Positive % Agreement (95% CI)	Negative % Agreement (95% CI)	Overall % Agreement (95% CI)
Sym.	Swab	Female*	133	63	1	1	68	98.4 (91.6–100)	98.6 (92.2–100)	98.5 (94.7–99.8)
		Male	60	42	0	0	18	100 (91.6–100)	100 (81.5–100)	100 (94.0–100)
	Urine	Female	56	33	0	1 ¹	22	100 (89.4–100)	95.7 (78.1–99.9)	98.2 (90.4–100)
		Male	60	41	0	0	19	100 (91.4–100)	100 (82.4–100)	100 (94.0–100)
	PreservCyt Solution		Female	81	39	0	42	100 (91.0–100)	100 (91.6–100)	100 (95.5–100)
Asym.	Swab	Female*	72	41	0	0	31	100 (91.4–100)	100 (88.8–100)	100 (95.0–100)
		Male	60	23	0	0	37	100 (85.2–100)	100 (90.5–100)	100 (94.0–100)
	Urine	Female	42	23	0	0	19	100 (85.2–100)	100 (82.4–100)	100 (91.6–100)
		Male	55	20	0	0	35	100 (83.2–100)	100 (90.0–100)	100 (93.5–100)
	PreservCyt Solution		Female	35	25	0	10	100 (86.3–100)	100 (69.2–100)	100 (90.0–100)
All	Swab	Female*	205	104	1	1	99	99.0 (94.8–100)	99.0 (94.6–100)	99.0 (96.5–99.9)
		Male	120	65	0	0	55	100 (94.5–100)	100 (93.5–100)	100 (97.0–100)
	Urine	Female	98	56	0	1 ¹	41	100 (93.6–100)	97.6 (87.4–99.9)	99.0 (94.4–100)
		Male	115	61	0	0	54	100 (94.1–100)	100 (93.4–100)	100 (96.8–100)
	PreservCyt Solution		Female	116	64	0	52	100 (94.4–100)	100 (93.2–100)	100 (96.9–100)

Sym = symptomatic; Asym= asymptomatic; CI = confidence interval.

“+” denotes a positive result, “-” a negative result.

*Endocervical and Vaginal Swab samples combined.

¹Specimen had a final equivocal result on the Tigris DTS System.

Analytical Performance

Spiked Clinical Panel Agreement Study

Individual negative urine specimens were spiked with CT serovar G to create a panel of 120 CT positives. CT positive panel members were spiked with organisms at 0.25 IFU/mL, 2.5 IFU/mL or 25 IFU/mL (0.5 fg/assay, 5 fg/assay or 50 fg/assay). In addition, 120 CT negative urine specimens were collected. The positive and negative panels were tested on three Panther and three Tigris DTS systems. Positive percent agreement between the Panther system and the Tigris DTS system was 100% with a lower 95% confidence interval of 98.9 for CT. Negative percent agreement between the Panther system and the Tigris DTS systems was 100% with a lower 95% confidence interval of 98.9. The results of the study are shown in Table 14.

Table 14: Spiked Clinical Panel Agreement Study: Agreement with Expected CT Results

Panel Member	Concentration		Replicates	Tigris % Agrmt	Panther % Agrmt
	IFU/mL	fg/assay			
Very Low Positive	0.25	0.5	120	100	100
Low Positive	2.5	5	120	100	100
Medium Positive	25	50	120	100	100
Negative	0	0	360	100	100

Overall Positive Percent Agreement between Tigris and Panther (95% CI): 100% (98.9–100).

Overall Negative Percent Agreement between Tigris and Panther (95% CI): 100% (98.9–100).

Analytical Sensitivity Study

C. trachomatis analytical sensitivity (limit of detection) was determined by directly comparing dilutions of CT organisms in cell culture and in the Aptima CT assay. The analytical sensitivity claim for the assay is one Inclusion-Forming Unit (IFU) per assay (7.25 IFU/swab, 5 IFU/mL urine, and 9.75 IFU/mL PreservCyt solution Pap) for all 15 CT serovars (A, B, Ba, C, D, E, F, G, H, I, J, K, L1, L2 and L3). However, dilutions of less than one IFU/assay of all serovars tested positive.

Analytical sensitivity of the Aptima CT assay was tested using three representative sample matrices. These were urine processed with Urine Transport Medium (UTM), PreservCyt solution Pap diluted with Swab Transport Medium and STM. CT rRNA was spiked into pools of these three matrices at the following concentrations 0.5 fg/assay, 5 fg/assay and 50 fg/assay (rRNA equivalents of 0.25 IFU/mL, 2.5 IFU/mL or 25 IFU/mL). The rRNA equivalents were calculated based on the genome size and estimated DNA:RNA ratio/cell of each organism. These panels were tested on three Panther systems using two lots of reagents in replicates of 96. Positive agreement with the expected result was calculated. Agreement to expected results was 100% (95% CI 96.2–100%) for all urine panels, 100% (95% CI 96.1–100%) for all PreservCyt solution Pap solution panels, and 100% for the (95% CI 96.0–100%) for all STM panels. The analytical sensitivity for the assay is 2.5 IFU/mL.

Analytical Specificity

A total of 154 culture isolates were evaluated using the Aptima CT assay. These isolates included 86 organisms that may be isolated from the urogenital tract and 68 additional organisms that represent a phylogenetic cross-section of organisms. The tested organisms included bacteria, fungi, yeast, parasites and viruses. All organisms except *C. psittaci*, *C.*

pneumoniae, *U. urealyticum* and the viruses were tested at 1.0×10^6 cells/assay in KOVA-Trol/Urine Transport Media and 60 organisms were tested in Swab Transport Media. The Chlamydia and Neisseria organisms were tested in the PreservCyt Solution media. *C. psittaci* VR601 was tested at 8.0×10^4 cells/assay and *C. psittaci* VR125 was tested at 1.0×10^5 cells/assay. *C. pneumoniae* was tested at 4×10^3 cells/assay and *U. urealyticum* was tested at 6.7×10^6 cells/assay. The viruses were tested as follows: (a) herpes simplex virus I: 2.5×10^4 TCID₅₀/assay, (b) herpes simplex virus II: 6.0×10^4 TCID₅₀/assay, (c) human papillomavirus 16: 2.9×10^6 DNA copies/assay and (d) cytomegalovirus: 4.8×10^5 cells/assay. The list of organisms tested is shown in Table 15.

Table 15: Analytical Specificity

Organism	Organism	Organism
<i>Achromobacter xerosis</i>	<i>Escherichia coli</i>	<i>Neisseria mucosa</i> (3)
<i>Acinetobacter calcoaceticus</i>	<i>Flavobacterium meningosepticum</i>	<i>Neisseria sicca</i> (3)
<i>Acinetobacter lwoffii</i>	<i>Fusobacterium nucleatum</i>	<i>Neisseria subflava</i> (14)
<i>Actinomyces israelii</i>	<i>Gardnerella vaginalis</i>	<i>Neisseria perflava</i>
<i>Actinomyces pyogenes</i>	<i>Gemella haemolysans</i>	<i>Neisseria polysaccharea</i>
<i>Aerococcus viridans</i>	<i>Haemophilus ducreyi</i>	<i>Paracoccus denitrificans</i>
<i>Aeromonas hydrophila</i>	<i>Haemophilus influenzae</i>	<i>Peptostreptococcus anaerobius</i>
<i>Agrobacterium radiobacter</i>	Herpes simplex virus I	<i>Peptostreptococcus productus</i>
<i>Alcaligenes faecalis</i>	Herpes simplex virus II	<i>Plesiomonas shigelloides</i>
<i>Bacillus subtilis</i>	Human papilloma virus 16	<i>Propionibacterium acnes</i>
<i>Bacteriodes fragilis</i>	<i>Kingella dentrificans</i>	<i>Proteus mirabilis</i>
<i>Bacteriodes ureolyticus</i>	<i>Kingella kingae</i>	<i>Proteus vulgaris</i>
<i>Bifidobacterium adolescentis</i>	<i>Klebsiella oxytoca</i>	<i>Providencia stuartii</i>
<i>Bifidobacterium brevi</i>	<i>Klebsiella pneumoniae</i>	<i>Pseudomonas aeruginosa</i>
<i>Branhamella catarrhalis</i>	<i>Lactobacillus acidophilus</i>	<i>Pseudomonas fluorescens</i>
<i>Brevibacterium linens</i>	<i>Lactobacillus brevis</i>	<i>Pseudomonas putida</i>
<i>Campylobacter jejuni</i>	<i>Lactobacillus jensonii</i>	<i>Rahnella aquatilis</i>
<i>Candida albicans</i>	<i>Lactobacillus lactis</i>	<i>Rhodospirillum rubrum</i>
<i>Candida glabrata</i>	<i>Legionella pneumophila</i> (2)	<i>Saccharomyces cerevisiae</i>
<i>Candida parapsilosis</i>	<i>Leuconostoc paramensenteroides</i>	<i>Salmonella minnesota</i>
<i>Candida tropicalis</i>	<i>Listeria monocytogenes</i>	<i>Salmonella typhimurium</i>
<i>Chlamydia pneumoniae</i>	<i>Micrococcus luteus</i>	<i>Serratia marcescens</i>
<i>Chlamydia psittaci</i> (2)	<i>Moraxella lacunata</i>	<i>Staphylococcus saprophyticus</i>
<i>Chromobacterium violaceum</i>	<i>Moraxella osloensis</i>	<i>Staphylococcus aureus</i>
<i>Citrobacter freundii</i>	<i>Morganella morganii</i>	<i>Staphylococcus epidermidis</i>
<i>Clostridium perfringens</i>	<i>Mycobacterium smegmatis</i>	<i>Streptococcus agalactiae</i>
<i>Corynebacterium genitalium</i>	<i>Mycoplasma genitalium</i>	<i>Streptococcus bovis</i>
<i>Corynebacterium xerosis</i>	<i>Mycoplasma hominis</i>	<i>Streptococcus mitis</i>
<i>Cryptococcus neoformans</i>	<i>N. meningitidis</i> Serogroup A	<i>Streptococcus mutans</i>
Cytomegalovirus	<i>N. meningitidis</i> Serogroup B	<i>Streptococcus pneumoniae</i>
<i>Deinococcus radiodurans</i>	<i>N. meningitidis</i> Serogroup C (4)	<i>Streptococcus pyogenes</i>
<i>Derxia gummosa</i>	<i>N. meningitidis</i> Serogroup D	<i>Streptococcus salivarius</i>
<i>Eikenella corrodens</i>	<i>N. meningitidis</i> Serogroup Y	<i>Streptococcus sanguis</i>
<i>Enterobacter aerogenes</i>	<i>N. meningitidis</i> Serogroup W135	<i>Streptomyces griseinus</i>
<i>Enterobacter cloacae</i>	<i>Neisseria cinerea</i> (4)	<i>Trichomonas vaginalis</i>
<i>Enterococcus avium</i>	<i>Neisseria dentrificans</i>	<i>Ureaplasma urealyticum</i>
<i>Enterococcus faecalis</i>	<i>Neisseria elongata</i> (3)	<i>Vibrio parahaemolyticus</i>
<i>Enterococcus faecium</i>	<i>Neisseria flava</i>	<i>Yersinia enterocolitica</i>
<i>Erwinia herbicola</i>	<i>Neisseria flavescens</i> (2)	
<i>Erysipelothrix rhusiopathiae</i>	<i>Neisseria lactamica</i> (9)	

(n) = number of strains tested. All organisms tested produced a negative result in the Aptima CT Assay.

Analytical Specificity Equivalence Study

For a nucleic acid amplification assay, analytical specificity with respect to individual organisms is largely determined by the chemistry of the assay (e.g. oligonucleotide sequences) rather than by the platform. Because the reagents for the Aptima CT assay are identical between the Panther system, Tigris DTS system and the DTS systems, analytical specificity experiments on the Panther system were designed to focus on the most challenging culture isolates. These organisms included those known to cross-react in other amplification assays. Twenty-five (25) culture isolates were selected from the panel of organisms in Table 15. All of the organisms tested produced negative results.

Interfering Substances

The following interfering substances were individually spiked into swab, PreservCyt solution Pap and/or urine specimens: 10% blood, contraceptive jelly, spermicide, moisturizer, hemorrhoidal anesthetic, body oil, powder, anti-fungal cream, vaginal lubricants, feminine spray and leukocytes (1×10^6 cells/mL). The following interfering substances were individually spiked into urine specimens: 30% blood, urine analytes, protein, glucose, ketones, bilirubin, nitrate, urobilinogen, pH 4 (acidic), pH 9 (alkaline), leukocytes (1×10^6 cells/mL), cellular debris, vitamins, minerals, acetaminophen, aspirin and ibuprofen. All were tested for potential assay interference in the absence and presence of CT at the estimated rRNA equivalent of 1 cell/assay (5 fg/assay). The rRNA equivalents were calculated based on the genome size and estimated DNA:RNA ratio/cell of each organism. No interference was observed with any of the tested substances. No inhibitors of amplification were observed in the Aptima CT assay.

Interfering Substances Equivalence Study

Blood commonly found in urogenital specimens may interfere in some amplification assays. Whole blood was used to establish the degree of blood interference on the Panther system with respect to this potential interferant. Fresh blood was added to clinical pools of vaginal swab specimens, post-processed PreservCyt solution Pap specimens or urine specimens and then tested for potential assay interference in the presence and absence of CT target. The estimated rRNA equivalent of one (1) CT IFU/assay (5 fg/assay) was used as the target concentration as this represents the analytical sensitivity of the assay. Specimens were tested on the Panther system. All samples containing target nucleic acid were positive when tested at a level of 10% (vol/vol) blood in swab or PreservCyt solution Pap specimens, or 30% (vol/vol) blood in urine specimens. All samples that did not contain target were correctly identified as negative. These results are identical to those demonstrated for the Tigris DTS system when spiked with the same quantities of blood. Blood added to swab, PreservCyt solution, and urine specimens at levels much higher than could be expected with normal specimen collection did not interfere with results on the Panther system.

Recovery

Escherichia coli, *Gardnerella vaginalis*, *Lactobacillus acidophilus*, *Bacteroides ureolyticus*, and *Staphylococcus epidermidis* (1×10^8 cells/assay) were added to samples containing the rRNA equivalent of approximately one CT IFU (5 fg). These additions did not interfere with the amplification and detection of CT rRNA using the Aptima CT assay.

Precision/Reproducibility Study

The Aptima CT assay precision was evaluated across three Panther systems and two Aptima CT assay kit lots over a period of 24 days. Panels were made by spiking CT rRNA

into STM at the concentrations shown in Table 16. Operators performed two runs per day running each panel member in replicates of two per run. The agreement with the expected result was calculated and precision was estimated according to NCCLS Guidelines EP5-A2 (17). The total number of replicates for each panel was 93–96. Table 16 presents the precision RLU data in terms of Mean, Standard Deviation, Coefficient of Variation (CV), percent agreement with expected results and calculations of between-instrument, between-lot, between-run, and within-run variability.

Table 16: Panther Precision for Aptima CT Assay

Matrix	CT (IFU/mL)	N*	Mean RLU (x1000)	% Agrmt	Between-instrument		Between-lot		Between-Run		Within-Run		Total	
					SD (x1000)	CV (%)	SD (x1000)	CV (%)	SD (x1000)	CV (%)	SD (x1000)	CV (%)	SD (x1000)	CV (%)
STM	0	96	2	100	0.38	21.3	0.64	35.8	0	0	1.86	104.6	2	112.3
	0.25	93	7390	100	221.74	3	264.35	3.6	0	0	180.07	2.4	389.2	5.3
	2.5	96	7478	100	224.45	3	249.88	3.3	53.1	0.7	164.57	2.2	377.8	5.1
	25	96	7482	100	222.23	3	233.36	3.1	46.47	0.6	180.29	2.4	372.2	5
Urine	0	95	2	100	0.23	12.7	0.38	20.7	0.52	28.5	1.3	71	1.5	81.9
	0.25	96	6978	100	276.94	4	330.57	4.7	66.36	1	264.73	3.8	510.4	7.3
	2.5	95	7291	100	121.2	1.7	154.63	2.1	73.51	1	148.13	2	256.8	3.5
	25	95	7349	100	121.57	1.7	181.34	2.5	66.87	0.9	162.45	2.2	280.2	3.8
PreservCyt Solution	0	96	7	97.9	3.36	46.1	0.29	4	0	0	20.52	281.4	20.8	285.3
	0.25	96	6996	100	225.16	3.2	209.86	3	0	0	164.87	2.4	349.2	5
	2.5	95	7079	100	246.89	3.5	172.55	2.4	0	0	151.67	2.1	337.2	4.8
	25	96	7050	100	262.52	3.7	167.79	2.4	0	0	192.5	2.7	366.2	5.2

RLU = relative light unit; % Agrmt = % agreement; CV% = percent coefficient of variation; SD = standard deviation.

Note: Variability from some factors may be numerically negative, which can occur if the variability due to those factors is very small. When this occurs, SD=0 and CV=0%.

* Total number of replicates for each panel = 96. In select runs, individual invalid replicates were not retested.

Carryover Study

To establish that the Panther system minimizes the risk of false positive results arising from carryover contamination, a multi-run analytical study was conducted using spiked panels on three Panther systems. Carryover was assessed using approximately 20% high titer CT samples dispersed between negative samples. The runs included clusters of high positive samples with clusters of negative samples as well as single high positives dispersed in a specific pattern within the run. High titer samples were made using CT rRNA spiked into STM to give a final concentration of 5×10^5 fg rRNA/reaction (rRNA equivalent of 2.5×10^5 IFU/mL). Testing was carried out using 5 runs on three Panther systems with a total of 2933 negative samples. The overall carryover rate was 0% with a 95% confidence interval of 0–0.1%. A total of 7 negative samples were reported as invalid in the high titer carryover runs and were excluded from the calculation.

Specimen Stability Studies

A. Swab Specimens

Data to support the recommended shipping and storage conditions for endocervical, urethral and vaginal swab samples were generated with pooled negative swab samples.

Pooled samples were spiked with CT at a final concentration of 1 IFU per reaction. The spiked samples were held at 4°C and 30°C. Samples were tested in duplicate at days 0, 20, 77, and 117. All test conditions were positive for CT at all times and temperatures.

B. Urine Specimens

Data to support the recommended shipping and storage conditions for urine samples were generated with female and male negative urine samples. The urine samples were spiked with CT at a final concentration of 10 IFU per reaction. Two sets of the spiked urine samples were held at 30°C prior to being added to the Urine Transport Media (UTM). The two sets of UTM samples then were held at 4°C and 30°C and tested in triplicate at days 0, 1, 5, 20, and 35. All UTM samples were positive for CT at all timepoints.

C. PreservCyt Solution Pap Specimens

Data to support the recommended shipping and storage conditions for PreservCyt solution Pap samples were generated with negative processed and unprocessed Pap samples. For the unprocessed samples, four pools of PreservCyt solution samples were tested after being stored in the PreservCyt solution vial. Each specimen pool was spiked with 1 to 10 IFU CT/assay, held at 2°C, 10°C, and 30°C, then tested at baseline and on days 5, 7, 8, 14, 18, 21, 25 and 36. All of the spiked samples were positive for CT at all times and temperatures.

For the processed samples, four pools of PreservCyt solution samples were used to determine processed specimen stability at 2°C to 30°C. Each negative sample pool was spiked with 1 to 10 IFU CT/assay, then tested at baseline. Prior to processing, the PreservCyt solution samples were stored at 30°C for seven (7) days to simulate the time lapse between sample collection, Pap processing and shipment to a microbiology testing lab. After seven days at 30°C, 1 mL aliquots of each pool were transferred to an Aptima specimen transfer tube and tested at baseline before being placed at 2°C, 10°C, and 30°C. The processed samples were then tested for 17 days stored at 30°C and 36 days stored at 2°C to 10°C. All of the spiked samples were positive for CT at all times and temperatures.

D. Additional Frozen (at –20°C) Specimen Stability Study

The recommended frozen storage conditions for endocervical swab, urethral swab, vaginal swab, female urine, male urine, and PreservCyt solution Pap specimens in transport media is between –20°C and –70°C to allow testing up to 12 months after collection. Supporting data for each specimen type were generated using 90 negative specimens. Of these, 30 specimens were spiked with CT at 1.0 IFU per reaction; 30 specimens were spiked at 0.1 IFU per reaction; and 30 specimens were not spiked. The specimens in transport media were stored frozen within 7 days of collection and tested at days 200 and 400. Specimens met the acceptance criteria of 95% agreement with expected results.

Bibliography

1. **Beem, M. O., and E. M. Saxon.** 1977. Respiratory tract colonization and a distinctive pneumonia syndrome in infants infected with *Chlamydia trachomatis*. *NEJM* **296**:306-310.
2. **Buimer, M., G. J. J. Van Doornum, S. Ching, P. G. H. Peerbooms, P. K. Plier, D. Ram, and H. H. Lee.** 1996. Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* by Ligase chain reaction-based assays with clinical specimens from various sites: implications for diagnostic testing and screening. *J. Clin. Microbiol.* **34**:2395-2400.
3. **Cates, Jr., W., and J. N. Wasserheit.** 1991. Genital chlamydia infections: epidemiology and reproductive sequelae. *Am. J. Obstet. Gynecol.* **164**:1771-1781.
4. **Centers for Disease Control and Prevention.** Sexually Transmitted Disease Surveillance 2020. Last reviewed April 12, 2022. Accessed December 7, 2022. <https://www.cdc.gov/std/statistics/2020/overview.htm>.
5. **Chernesky, M. A., D. Jang, J. Sellors, K. Luinstra, S. Chong, S. Castriciano, and J. B. Mahony.** 1996. Urinary inhibitors of polymerase chain reaction and Ligase chain reaction and testing of multiple specimens may contribute to lower assay sensitivities for diagnosing *Chlamydia trachomatis* infected women. *Mol. Cell. Probes.* **11**:243-249.
6. **Chong, S., D. Jang, X. Song, J. Mahony, A. Petrich, P. Barriga, and M. Chernesky.** 2003. Specimen processing and concentration of *Chlamydia trachomatis* added can influence false-negative rates in the LCx assay but not in the APTIMA Combo 2 Assay when testing for inhibitors. *J. Clin. Microbiol.* **41**:778-782.
7. **Crotchfelt, K. A., B. Pare, C. Gaydos, and T. C. Quinn.** 1998. Detection of *Chlamydia trachomatis* by the Hologic AMPLIFIED Chlamydia Trachomatis assay (AMP CT) in urine specimens from men and women and endocervical specimens from women. *J. Clin. Microbiol.* **36**:391-394.
8. **Frommelt, G. T., R. Rothenberg, S. Wang, and K. McIntosh.** 1979. Chlamydial infection of mothers and their infants. *Journal of Pediatrics* **95**:28-32.
9. **Gaydos, C. A., T.C. Quinn, D. Willis, A. Weissfeld, E. W. Hook, D. H. Martin, D. V. Ferraro, and J. Schachter.** 2003. Performance of the APTIMA Combo 2 Assay for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in female urine and endocervical swab specimens. *J. Clin. Microbiol.* **41**:304-309.
10. **Goessens, W. H. F., J. W. Mouton, W. I. Van Der Meijden, S. Deelen, T. H. Van Rijsoort-Vos, N. L. Toom, H. Verbrugh, and R. P. Verkooyen.** 1997. Comparison of three commercially available amplification assays, AMP CT, LCx, and COBAS AMPLICOR, for detection of *Chlamydia trachomatis* in first-void urine. *J. Clin. Microbiol.* **35**:2628-2633.
11. **Holmes, K. K., H. H. Handsfield, S. P. Wang, B. B. Wentworth, M. Turck, J. B. Anderson, and E. R. Alexander.** 1975. Etiology of nongonococcal urethritis. *NEJM* **292**:1199-1205.
12. **Jaschek, G., C. A. Gaydos, L. E. Welsh, and T. C. Quinn.** 1993. Direct detection of *Chlamydia trachomatis* in urine specimens from symptomatic and asymptomatic men by using a rapid polymerase chain reaction assay. *J. Clin. Microbiol.* **31**:1209-1212.
13. **Mahony, J., S. Chong, D. Jang, K. Luinstra, M. Faught, D. Dalby, J. Sellors, and M. Chernesky.** 1998. Urine specimens from pregnant and nonpregnant women inhibitory to amplification of *Chlamydia trachomatis* nucleic acid by PCR, Ligase chain reaction, and transcription-mediated amplification: identification of urinary substances associated with inhibition and removal of inhibitory activity. *J. Clin. Microbiol.* **36**:3122-3126.
14. **McCurdy, Brenda W.** 1997. Cumitech Guide on Verification and Validation of Procedures in the Microbiology Laboratory. February, 1997, American Society for Microbiology. ASM Press.
15. **National Committee for Clinical Laboratory Standards.** 1999. NCCLS EP5-A: Evaluation of Precision Performance of Clinical Chemistry Devices; Approved Guideline (Vol. 19, No. 2).
16. **National Committee for Clinical Laboratory Standards.** 2002. User Protocol for Evaluation of Qualitative Test Performance: Approved Guideline for additional Guidance on Appropriate Internal Quality Control Testing Practices.
17. **National Committee for Clinical Laboratory Standards.** 2004. NCCLS EP5-A2: Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline (2nd edition, Vol. 24, No. 25).
18. **Peterson E. M., V. Darrow, J. Blanding, S. Aarnaes, and L. M. de La Maza.** 1997. Reproducibility problems with the AMPLICOR PCR *Chlamydia trachomatis* test. *J. Clin. Microbiol.* **35**:957-959.
19. **Schachter, J.** 1985. Chlamydiae (Psittacosis-Lymphogranuloma Venereum-Trachoma group), p. 856-862. *In* E. H. Lennette, et al. (ed.), *Manual of Clinical Microbiology*, 4th ed. American Society for Microbiology, Washington, D.C.
20. **Schachter, J., and M. Grossman.** 1981. chlamydial infections. *Ann. Rev. Med.* **32**:45-61.
21. **Schachter, J.** 1978. Medical progress: chlamydial infections (third of three parts). *NEJM* **298**:540-549.
22. **Schachter, J., E. C. Hill, E. B. King, V. R. Coleman, P. Jones, and K. F. Meyer.** 1975. Chlamydial infection in women with cervical dysplasia. *Am. J. Obstet. Gynecol.* **123**:753-757.
23. **Stary, A., E. Schuh, M. Kerschbaumer, B. Gotz, and H. Lee.** 1998. Performance of transcription-mediated amplification and Ligase chain reaction assays for detection of chlamydial infection in urogenital samples obtained by invasive and noninvasive methods. *J. Clin. Microbiol.* **36**:2666-2670.
24. **Toye, B., W. Woods, M. Bobrowska, and K. Ramotar.** 1998. Inhibition of PCR in genital and urine specimens submitted for *Chlamydia trachomatis* testing. *J. Clin. Microbiol.* **36**:2356-2358.
25. **Verkooyen, R. P., A. Luijendijk, W. M. Huisman, W. H. F. Goessens, J. A. J. W. Kluytmans, J. H. Rijsoort-Vos, and H. A. Verbrugh.** 1996. Detection of PCR inhibitors in cervical specimens by using the AMPLICOR *Chlamydia trachomatis* assay. *J. Clin. Microbiol.* **34**:3072-3074.

26. **Vincelette, J., J. Schirm, M. Bogard, A. Bourgault, D. Luijt, A. Bianchi, P. C. Van Voorst Vader, A. Butcher, and M. Rosenstrauss.** 1999. Multicenter evaluation of the fully automated COBAS AMPLICOR PCR test for detection of *Chlamydia trachomatis* in urogenital specimens. *J. Clin. Microbiol.* **3**:74-80.
27. **Yuan, Y., Y-X. Zhang, N. G. Watkins, and H. D. Caldwell.** 1989. Nucleotide and deduced amino acid sequences for the four variable domains of the major outer membrane proteins of the 15 *Chlamydia trachomatis* serovars. *Infect. Immun.* **57**:1040-1049.

Contact Information and Revision History



Hologic, Inc.
10210 Genetic Center Drive
San Diego, CA 92121 USA



EC REP
Hologic BV
Da Vincilaan 5
1930 Zaventem
Belgium

Australian Sponsor
Hologic (Australia & New
Zealand) Pty Ltd.
Macquarie Park NSW 2113

For country-specific Technical Support and Customer Service email address and telephone number, visit www.hologic.com/support.

Serious incidents occurring in relation to the device in the European Union should be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

Hologic, Aptima, Aptima Combo 2, DTS, PreservCyt, Panther, Panther Fusion, ThinPrep, Tigris, and TMA are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

KOVA-TROL is a trademark of Hycor Biomedical, Inc.

All other trademarks that may appear in this package insert are the property of their respective owners.

This product may be covered by one or more U.S. patents identified at www.hologic.com/patents.

© 2024 Hologic, Inc. All rights reserved.

AW-29039-001 Rev. 006
2024-09

Revision History	Date	Description
AW-29039 Rev. 005	April 2024	<ul style="list-style-type: none">Creation of an Aptima CT Assay IFU AW-29039 Rev. 005 (Ex-US) using Aptima CT Assay IFU AW-29039 Rev. 004. Rev. 005, not Rev. 003 or Rev. 004, will replace 502184EN Rev. 010.Corrected an administrative error in Table 6g.
AW-29039 Rev. 006	September 2024	<ul style="list-style-type: none">Creation of an IVDR-compliant Aptima CT Assay IFU AW-29039 Rev. 006 (Ex-US) using an IVDR-compliant Aptima CT Assay IFU AW-29039 Rev. 005. Rev. 006, not Rev. 005, Rev. 004, or Rev. 003, will replace 502184EN Rev. 010.Corrected the SDS section of this IFU.Corrected an administrative error in Table 3.